Combination of vulgar pemphigus and toxic epidermal necrolysis: a case report ; Клиническое наблюдение сочетанного течения вульгарной пузырчатки и токсического эпидермального некролиза

Authors: Molochkov A.V., Kupriyanova A.G., Karzanov O.V., Setdikova G.R., Bolshakova E.A., Kornyushenko V.O., Molochkov V.A.

Contributors: 1

Source: Almanac of Clinical Medicine; Vol 53, No 3 (2025); 160-167 ; Альманах клинической медицины; Vol 53, No 3 (2025); 160-167 ; 2587-9294 ; 2072-0505

Subject Terms: pemphigus vulgaris, rituximab, toxic epidermal necrolysis, biological targeted therapy, вульгарная пузырчатка, ритуксимаб, токсический эпидермальный некролиз, генно-инженерная биологическая терапия

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/17546/1752; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160674; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160697; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160698; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160699; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160700; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160701; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160702; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160703; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160704; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160705; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160706; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160707; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160708; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160709; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160710; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160711; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160712; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160713; https://almclinmed.ru/jour/article/downloadSuppFile/17546/160714; https://almclinmed.ru/jour/article/view/17546

Availability: https://almclinmed.ru/jour/article/view/17546
https://doi.org/10.18786/2072-0505-2025-53-018

Ustekinumab Efficacy in Children with Palmoplantar Psoriasis: Case Series ; Эффективность устекинумаба при ладонно-подошвенном псориазе у детей: серия клинических случаев

Authors: Maria A. Leonova, Nikolay N. Murashkin, Alexander I. Materikin, Roman V. Epishev, Dmitriy V. Fedorov, Leonid A. Opryatin, Roman A. Ivanov, Ekaterina S. Pavlova, М. А. Леонова, Н. Н. Мурашкин, А. И. Материкин, Р. В. Епишев, Д. В. Федоров, Л. А. Опрятин, Р. А. Иванов, Е. С. Павлова

Contributors: Not declared., Отсутствует.

Source: Current Pediatrics; Том 23, № 5 (2024); 370-375 ; Вопросы современной педиатрии; Том 23, № 5 (2024); 370-375 ; 1682-5535 ; 1682-5527

Subject Terms: устекинумаб, palmoplantar psoriasis, methotrexate, genetically engineered biologic therapy, ustekinumab, ладонно-подошвенный псориаз, метотрексат, генно-инженерная биологическая терапия

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3611/1405; Gunter NV, Yap BJM, Chua CLL, Yap WH. Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients. Front Genet. 2019;10:395. doi: https://doi.org/10.3389/fgene.2019.00395; Мурашкин Н.Н., Круглова Л.С., Коваленко Ю.А. и др. Коморбидности псориаза в детском возрасте // Вопросы современной педиатрии. — 2020. — Т. 19. — № 6. — С. 460–467. — doi: https://doi.org/10.15690/vsp.v19i6.2149; Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: https://doi.org/10.1111/pde.13772; Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8:743180. doi: https://doi.org/10.3389/fmed.2021.743180; Kang BY, O’Haver J, Andrews ID. Pediatric Psoriasis Comorbidities: Screening Recommendations for the Primary Care Provider. J Pediatr Health Care. 2021;35(3):337–350. doi: https://doi.org/10.1016/j.pedhc.2020.12.006; Branisteanu DE, Georgescu S, Serban IL, et al. Management of psoriasis in children (Review). Exp Ther Med. 2021;22(6):1429. doi: https://doi.org/10.3892/etm.2021.10864; Elvina M. Pediatric Psoriasis: Clinical Features and Course. Open Acc J Bio Sci. 2020;1(5):207–209. doi: https://doi.org/10.38125/OAJBS.000147; Montes de Oca Pedrosa A, Oakley A, Rogers J, Rangaitaha Epiha M. PASI vs PO-PASI: Patient-Oriented PASI (PO-PASI) is comparable to clinician score PASI. Australas J Dermatol. 2022;63(1):e67–e70. doi: https://doi.org/10.1111/ajd.13738; Torrelo A. The use of biologics for childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1816. doi: https://doi.org/10.1111/jdv.15855. PMID: 31617632; Иванов Р.А., Мурашкин Н.Н. Выживаемость биологической терапии у детей, страдающих псориазом: когортное исследование // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 451–458. — doi: https://doi.org/10.15690/vsp.v20i5.2323; Мурашкин Н.Н., Амбарчян Э.Т. Сравнительная оценка эффективности и безопасности ингибиторов TNFα и IL12/23 в терапии псориаза у детей // Педиатрическая фармакология. — 2018. — Т. 15. — № 6. — С. 455–463. — doi: https://doi.org/10.15690/pf.v15i6.1983; Мурашкин Н.Н., Амбарчян Э.Т., Епишев Р.В. и др. Эффективность и безопасность устекинумаба у детей с бляшечной, эритродермической и ладонно-подошвенной формами псориаза: ретроспективное когортное исследование // Вопросы современной педиатрии. — 2020. — Т. 19. — № 6. — С. 531–537. — doi: https://doi.org/10.15690/vsp.v19i6.2153; Chovatiya R, Silverberg JI. Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. Children (Basel). 2019;6(10):108. doi: https://doi.org/10.3390/children6100108; Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production 215 of interleukin-17. J Biol Chem. 2003;278(3):1910–1914. doi: https://doi.org/10.1074/jbc.M207577200; Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. doi: https://doi.org/10.1084/jem.20030451; Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: A systematic review and meta-analysis. Pediatr Dermatol. 2022;39(1):42–48. doi: https://doi.org/10.1111/pde.14870; Paller AS, Siegfried EC, Langley RG, et al. Long-Term Safety and Efficacy of Etanercept in Children and Adolescents with Plaque Psoriasis. J Am Acad Dermatol. 2016;74(2):280–287.e1–e3. doi: https://doi.org/10.1016/j.jaad.2015.09.056; Papp K, Thaçi D, Marcoux D, et al. Efficacy and Safety of Adalimumab Every Other Week versus Methotrexate Once Weekly in Children and Adolescents with Severe Chronic Plaque Psoriasis: a Randomised, Double-Blind, Phase 3 Trial. Lancet. 2017;390(10089):40–49. doi: https://doi.org/10.1016/S0140-6736(17)31189-3; Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–672. doi: https://doi.org/10.1111/bjd.19018; Magnolo N, Kingo K, Laquer V, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1): 122–130. doi: https://doi.org/10.1016/j.jaad.2021.08.066

Availability: https://vsp.spr-journal.ru/jour/article/view/3611
https://doi.org/10.15690/vsp.v23i5.2806

The problem of choosing a genetically engineered biological drug in a patient with severe bronchial asthma ; Проблема выбора генно-инженерного биологического препарата у пациента с тяжелой бронхиальной астмой

Authors: O. N. Titova, V. A. Volchkov, N. A. Kuzubova, D. B. Sklyarova, О. Н. Титова, В. А. Волчков, Н. А. Кузубова, Д. Б. Склярова

Source: Meditsinskiy sovet = Medical Council; № 23 (2023); 128-132 ; Медицинский Совет; № 23 (2023); 128-132 ; 2658-5790 ; 2079-701X

Subject Terms: иммуноглобулин Е, genetically engineered biological therapy, benralizumab, dupilumab, personalized medicine, eosinophilic inflammation, immunoglobulin E, генно-инженерная биологическая терапия, бенрализумаб, дупилумаб, персонализированная медицина, эозинофильное воспаление

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8011/7102; Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094. https://doi.org/10.1183/13993003.02094-2020.; Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013.; Trevor J, Lugogo N, Carr W, Moore C, Soong W, Panettieri Jr RA et al. Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments. Ann Allergy Asthma Immunology. 2021;127(5):579–587. https://doi.org/10.1016/j.anai.2021.07.010.; Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc. 2013;(10):143–149. https://doi.org/10.1513/Annal-sATS.201306-168AW.; Kaur R, Chupp GJ. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12. https://doi.org/10.1016/j.jaci.2019.05.031.; Ramírez-Jiménez F, Pavón-Romero GF, Velásquez-Rodríguez JM, López-Garza MI, Lazarini-Ruiz JF, Gutiérrez-Quiroz KV, Teran LM. Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future. Pharmaceuticals (Basel). 2023;16(2):270. https://doi.org/10.3390/ph16020270.; Kavanagh JE, Hearn AP, Jackson DJ. A pragmatic guide to choosing biologic therapies in severe asthma. Breathe (Sheff). 2021;17(4):210144. https://doi.org/10.1183/20734735.0144-2021.; Kavanagh JE, Hearn AP, Dhariwal J, d’Ancona G, Douiri A, Roxas C et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. https://doi.org/10.1016/j.chest.2020.08.2083.; Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. https://doi.org/10.1016/S0140-6736(16)31324-1.; FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. https://doi.org/10.1016/S01406736(16)31322-8.; Pham DN. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report. J Med Case Rep. 2021;15(1):103. https://doi.org/10.1186/s13256-021-02663-2.; Guttman-Yassky E, Bahadori L, Brooks L, Ckark L, Grindebacke H, Ho CN et al. Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial. J Eur Acad Dermatol Venereol. 2023;37(10):e1211–e1214. https://doi.org/10.1111/jdv.19195.; Alenazi SD. Atopic dermatitis: a brief review of recent advances in its management. Dermatol Reports. 2023;15(3):9678. https://doi.org/10.4081/dr.2023.9678.; Salter B, Lacy P, Mukherjee M. Biologics in Asthma: A Molecular Perspective to Precision Medicine. Front Pharmacol. 2022;(12):793409. https://doi.org/10.3389/fphar.2021.793409.; Sardon-Prado O, Diaz-Garcia C, Corcuera-Elosegui P, Korta-Murua J, Valverde-Molina J, Sanchez-Solis M. Severe Asthma and Biological Therapies: Now and the Future. J Clin Med. 2023;12(18):5846. https://doi.org/10.3390/jcm12185846.; Rogers L, Jesenak M, Bjermer L, Hanania NA, Seys SF, Diamant Z. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023;218:107414. https://doi.org/10.1016/j.rmed.2023.107414.; López-Viña A, Díaz Campos RM, Trisan Alonso A, Melero Moreno C. Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach. Front Allergy. 2022;(3):1007593. https://doi.org/10.3389/falgy.2022.1007593.

Availability: https://www.med-sovet.pro/jour/article/view/8011
https://doi.org/10.21518/ms2023-471

Netakimab in the treatment of psoriatic erythroderma ; Нетакимаб в терапии псориатической эритродермии

Authors: G. N. Tarasenko, I. V. Patronov, Г. Н. Тарасенко, И. В. Патронов

Source: Meditsinskiy sovet = Medical Council; № 14 (2024); 78-81 ; Медицинский Совет; № 14 (2024); 78-81 ; 2658-5790 ; 2079-701X

Subject Terms: псориатический артрит, genetically engineered biological therapy, pustular psoriasis, psoriatic arthritis, генно-инженерная биологическая терапия, пустулезный псориаз

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8536/7517; Кубанова АА, Кубанов АА, Самцов АВ, Аравийских ЕР. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс; 2016. 768 c. Режим доступа: https://studfile.net/preview/6439905.; Тарасенко ГН, Паценко МБ, Алехнович АВ. Генно-инженерная биологическая терапия псориаза: перспективное направление в военномедицинской организации. Госпитальная медицина: наука и практика. 2018;(1):75–78. Режим доступа: https://www.elibrary.ru/saunpw.; Grän F, Kerstan A, Serfling E, Goebeler M, Muhammad K, Grän F et al. Current Developments in the Immunology of Psoriasis. Yale J Biol Med. 2020;93(1):97–110. Available at: https://pubmed.ncbi.nlm.nih.gov/32226340.; Сарсур ШХР, Руднева НС. Результаты сравнения эффективности применения адалимумаба и иксекизумаба в лечении псориаза. Госпитальная медицина: наука и практика: 2024;7(1):17–22. Режим доступа: https://www.3hospital.ru/media/newspapers/1_2024_сайт.pdf; Молочков ВА, Бадокин ВВ, Альбанова ВИ, Волнухин ВА. Псориаз и псориатический артрит. М.: Товарищество научных изданий КМК; 2007. 300 с.; Кубанова АА (ред.). Псориаз: клинические рекомендации. М.: ДЭКС-Пресс; 2008. 56 с.; Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://doi.org/10.1136/bmj.m1590.; Голдсмит ЛА, Кац СИ, Джилкрест БА, Паллер ЭС, Леффель ДД, Вольф К (ред.). Дерматология Фицпатрика в клинической практике. М.: Издательство Панфилова: БИНОМ, Лаборатория знаний; 2012. Т., 1168 с.; Скрипкин ЮК (ред.). Кожные и венерические болезни. М.: ГЭОТАР-Медиа; 2012. 544 с. Режим доступа: http://www.studmedlib.ru/book/ISBN9785970419939.html.; Gianfredi V, Casu G, Bricchi L, Kacerik E, Rongioletti F, Signorelli C et al. Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients’ satisfaction. Acta Biomed. 2022;93(6):e2022332. https://doi.org/10.23750/abm.v93i6.13177.; Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Giannetti A et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008;217(3):268–275. https://doi.org/10.1159/000149970.; Augey F, Renaudier P, Nicolas JF. General pustular psoriasis: a French epidemiological survey. Eur J Dermatol. 2006;16(6):669–673. Available at: https://pubmed.ncbi.nlm.nih.gov/17229609.; Тарасенко ГН, Патронов ИВ. Клинический случай эффективного лечения вульгарного псориаза генно-инженерным биологическим препаратом у пациента с сердечной недостаточностью. Эффективная фармакотерапия. 2022;18(25):28–30. Режим доступа: https://umedp.ru/upload/iblock/7dd/effektivnaya_farmakoterapiya_dermatovenerologiya_i_dermatokosmetologiya_2_3_2022.pdf; Тарасенко ГН, Патронов ИВ. Поражение ногтей при псориазе и возможности терапии. Госпитальная медицина: наука и практика. 2022;5(4):10–12. Режим доступа: https://www.elibrary.ru/yaohia.; Тарасенко ГН, Паценко МБ, Патронов ИВ, Кузьмина ЮВ. Биологическая терапия как перспектива лечения тяжелых форм псориаза. Военномедицинский журнал. 2018;339(6):81–82. Режим доступа: https://www.elibrary.ru/xypoeh.; Тарасенко ГН, Белякин СА, Рыжман НН, Кузьмина ЮВ. Антицитокиновая терапия тяжелых форм псориаза в многопрофильном госпитале. Российский журнал кожных и венерических болезней. 2013;16(1):30–33. Режим доступа: https://rjsvd.com/1560-9588/article/view/36773/24568.; Weisenseel P, Prinz JC. Sequential use of inliximab and etanercept in generalized pustular psoriasis. Cutis. 2006;78(3):197–199. Available at: https://pubmed.ncbi.nlm.nih.gov/17036664.

Availability: https://www.med-sovet.pro/jour/article/view/8536
https://doi.org/10.21518/ms2024-335

Vaccination against Herpes zoster in patients with immune-mediated inflammatory rheumatic diseases: new data ; Вакцинопрофилактика опоясывающего лишая (Herpes zoster) у больных с иммуновоспалительными ревматическими заболеваниями: новые данные

Authors: N. V. Muravyova, B. S. Belov, Н. В. Муравьева, Б. С. Белов

Contributors: The article was prepared as part of the research work, government task №1021051503137-7., Статья подготовлена в рамках научно-исследовательской работы, № государственного задания 1021051503137-7.

Source: Modern Rheumatology Journal; Том 18, № 4 (2024); 115-120 ; Современная ревматология; Том 18, № 4 (2024); 115-120 ; 2310-158X ; 1996-7012

Subject Terms: рекомбинантная адъювантная вакцина, rheumatoid arthritis, systemic lupus erythematosus, glucocorticoids, Janus kinase inhibitors, biologic disease-modifying antirheumatic drugs, herpes zoster, vaccination, recombinant adjuvant vaccine, ревматоидный артрит, системная красная волчанка, глюкокортикоиды, ингибиторы Янус-киназ, генно-инженерная биологическая терапия, опоясывающий лишай, вакцинация

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1629/1505; Ющук НД, Венгеров ЮЯ, редакторы. Инфекционные болезни: национальное руководство. Москва: ГЭОТАР-Медиа; 2021.; Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015 Jul;3(4):109-20. doi:10.1177/2051013615599151.; Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019 Sep 19;5(2):e001041. doi:10.1136/rmdopen-2019-001041. eCollection 2019.; Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014 Apr;42(2): 325-34. doi:10.1007/s15010-013-0550-8. Epub 2013 Nov 10.; Dlamini ST, Htet KM, Theint ECC, et al. Herpes zoster risk in patients with rheumatoid arthritis and its association with medications used. Int J Environ Res Public Health. 2023 Jan 24;20(3):2123. doi:10.3390/ijerph20032123.; Liao TL, Lin CH, Chen HH, et al. Significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients. J Am Heart Assoc. 2017 Jul 19;6(7):e006304. doi:10.1161/JAHA.117.006304.; Nakajima A, Urano W, Inoue E, et al. Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol. 2015 Jul;25(4):558-61. doi:10.3109/14397595.2014.984829. Epub 2015 Feb 4.; Yamaguchi R, Tanaka E, Nakajima A, et al. Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids. Mod Rheumatol. 2022 Apr 18;32(3):522-527. doi:10.1093/mr/roab026.; Zhang N, Wilkinson S, Riaz M, et al. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol. 2012 Nov-Dec; 30(6):962-71. Epub 2012 Dec 17.; Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006 Nov;45(11): 1370-5. doi:10.1093/rheumatology/kel328. Epub 2006 Sep 26.; Mok CC, Ho LY, Tse SM, et al. Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies. Clin Rheumatol. 2023 Apr;42(4):1019-1026. doi:10.1007/s10067-022-06450-2. Epub 2022 Nov 16.; Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014 May; 81(3):215-21. doi:10.1016/j.jbspin.2013.07.009. Epub 2013 Aug 7.; Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022 Jan;81(1):41-47. doi:10.1136/annrheumdis2021-220651. Epub 2021 Jul 28.; Atzeni F, Gozza F, Riva A, et al. Conventional, biological disease-modifying antirheumatic drugs and Janus kinase inhibitors and varicella zoster virus. Expert Opin Pharmacother. 2023 Apr;24(6):679-689. doi:10.1080/14656566.2023.2195050. Epub 2023 Mar 28.; Sakai R, Kasai S, Hirano F, et al. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. Int J Rheum Dis. 2018 Sep;21(9):1670-1677. doi:10.1111/1756-185X.13300. Epub 2018 Apr 17.; Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct; 75(10):1843-7. doi:10.1136/annrheumdis2016-209131. Epub 2016 Apr 25.; Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol. 2022 Sep 23:13:996662. doi:10.3389/fimmu.2022.996662. eCollection 2022.; Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766. doi:10.1093/rheumatology/kez087.; Sanchez Gonzalez CO, Nieto Gonzalez JC. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature. Reumatol Clin (Engl Ed). 2022 Oct;18(8): 453-458. doi:10.1016/j.reumae.2021.06.001. Epub 2021 Dec 8.; Alves C, Penedones A, Mendes D, Marques FB. The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol. 2022 Mar 1;28(2):e407-e414. doi:10.1097/RHU.0000000000001749.; Gialouri CG, Moustafa S, Thomas K, et al. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and realworld studies. Rheumatol Int. 2023 Mar;43(3): 421-435. doi:10.1007/s00296-022-05270-6. Epub 2023 Jan 13.; Koh JH, Lee J, Kim SH, et al. Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis. J Rheumatol. 2018 Apr; 45(4):465-469. doi:10.3899/jrheum.170936. Epub 2018 Feb 1.; Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012 Jul 4;308(1):43-9. doi:10.1001/jama.2012.7304.; Calabrese LH, Abud Mendoza C, Stephen M, et al. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care Res (Hoboken). 2020 Mar;72(3):353-359. doi:10.1002/acr.24010.; Yun H, Xie F, Baddley JW, et al. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017 Jul; 44(7):1083-1087. doi:10.3899/jrheum.160685. Epub 2017 Mar 15.; Eberhardson M, Hall S, Papp KA, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis. 2017 Oct 1;65(7): 1174-1182. doi:10.1093/cid/cix484.; Venerito V, Stefanizzi P, Cantarini L, et al. Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study. Int J Mol Sci. 2023 Apr 9; 24(8):6967. doi:10.3390/ijms24086967.; Esteban-Vazquez A, Steiner M, Castaсeda E, et al. The real-world study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase inhibitors. Vaccines (Basel). 2023 Oct 18;11(10): 1610. doi:10.3390/vaccines11101610.; Källmark H, Bergström T, Nagel J, et al. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology (Oxford). 2024 Jul 1; 63(7):2024-2033. doi:10.1093/rheumatology/kead552.; Kojima S, Iwamoto T, Kobayashi Y, et al. Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs. RMD Open. 2024 Feb 21;10(1): e003902. doi:10.1136/rmdopen-2023-003902.; Andreica I, Reale S, Intini G, et al. Tolerability and safety of recombinant zoster vaccine in patients with inflammatory rheumatic musculoskeletal diseases – a prospective longitudinal study over 6 months. Ann Rheum Dis. 2023;82(suppl. 1):550. doi:10.1136/annrheumdis-2023-eular.2827.; Stevens E, Weinblatt ME, Massarotti E, et al. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients. ACR Open Rheumatol. 2020 Jun;2(6):357-361. doi:10.1002/acr2.11150. Epub 2020 May 15.; Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021 Nov 3;60(11):5149-5157. doi:10.1093/rheumatology/keab139.; Gupta S, Arasaratnam RJ, Solow EB, Bajaj P. A medical records review study assessing safety of zoster vaccine recombinant, adjuvanted in patients with rheumatic disease. J Clin Rheumatol. 2022 Mar 1;28(2):e528-e531. doi:10.1097/RHU.0000000000001790.; Pons-Bas A, Rosas J, Pons-Canet L, et al. Safety of the recombinant herpes zoster vaccine in patients with rheumatoid arthritis treated with JAKI drugs. Ann Rheum Dis. 2023;82(suppl. 1):2121. doi:10.1136/annrheumdis-2023-eular.1013.; Winthrop K, Klaff J, Liu Y, et al. Evaluation of response to adjuvant recombinant zoster vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a randomized trial sub-study. Ann Rheum Dis. 2023;82(suppl. 1):148. doi:10.1136/annrheumdis-2023-eular.2386.; Heineman TC, Cunningham A and Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019 Aug:59:42-48. doi:10.1016/j.coi.2019.02.009. Epub 2019 Apr 17.; Sieiro Santos C, Lopez Robles A, Alvarez Castro C, et al. Immune responses to vaccination against herpes zoster (HZ) in patients with rheumatic diseases under treatment with JAK-inhibitors: our preliminary results. Ann Rheum Dis. 2023;82(suppl. 1):1186. doi:10.1136/annrheumdis-2023-eular.998.; Mas Sanchez L, Munoz Martinez P, Grau Garcia E, et al. Experience in real-world conditions of the effectiveness of the vaccine against herpes zoster. Ann Rheum Dis. 2023; 82(suppl. 1):2027. doi:10.1136/annrheumdis2023-eular.4258.; Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023 Mar;75(3):333-348. doi:10.1002/art.42386. Epub 2023 Jan 4.; Pier M, Wolbink G, Boekel L. Time to talk to adults with rheumatic diseases about herpes zoster vaccination. Lancet Rheumatol. 2024 Apr;6(4):e247-e251. doi:10.1016/S2665-9913(24)00019-5. Epub 2024 Feb 16.

Availability: https://mrj.ima-press.net/mrj/article/view/1629
https://doi.org/10.14412/1996-7012-2024-4-115-120

Modern treatment options for systemic lupus erythematosus in children (literature review) ; Современные возможности лечения системной красной волчанки у детей (обзор литературы)

Authors: M. I. Kaleda, I. P. Nikishina, М. И. Каледа, И. П. Никишина

Contributors: Статья подготовлена в рамках фундаментальной темы №1021051302580-4.

Source: Modern Rheumatology Journal; Том 18, № 4 (2024); 99-105 ; Современная ревматология; Том 18, № 4 (2024); 99-105 ; 2310-158X ; 1996-7012

Subject Terms: детский возраст, glucocorticoids, biologic disease-modifying antirheumatic drugs, childhood, глюкокортикоиды, генно-инженерная биологическая терапия

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1627/1503; Mina R, Brunner HI. Pediatric lupus – are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010 Feb;36(1):53-80, vii-viii. doi:10.1016/j.rdc.2009.12.012.; Brunner HI, Vadhariya A, Dickson C, et al. Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. 2023 Jul;10(2):e000817. doi:10.1136/lupus-2022-000817.; Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):488-504. doi:10.1016/j.berh.2018.02.001. Epub 2018 Mar 1.; Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11): 1788-1796. doi:10.1136/annrheumdis-2016-210960. Epub 2017 Jun 19.; Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhoodonset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi:10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.; Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017 Oct;76(10):1637-1641. doi:10.1136/annrheumdis-2016-211001. Epub 2017 May 4.; Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-745. doi:10.1136/annrheumdis2019-215089. Epub 2019 Mar 29.; Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) Recommendations for the Management of Lupus Nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723. doi:10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27.; Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2; 83(1):15-29. doi:10.1136/ard-2023-224762.; Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019 Dec:209:108274. doi:10.1016/j.clim.2019.108274. Epub 2019 Oct 31.; Deng J, Chalhoub NE, Sherwin CM, et al. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019 Oct;49(2):251-259. doi:10.1016/j.semarthrit.2019.03.010. Epub 2019 Mar 16.; Smith EMD, Egbivwie N, Jorgensen AL, et al. Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. Clin Immunol. 2022 Jun:239:109028. doi:10.1016/j.clim.2022.109028. Epub 2022 May 2.; Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021 Jul; 23(4):331-347. doi:10.1007/s40272-021-00457-z. Epub 2021 Jul 10.; Rygg M, Pistorio A, Ravelli A, et al; Paediatric Rheumatology International Trials Organisation (PRINTO). A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis. 2012 Apr;71(4):511-7. doi:10.1136/annrheumdis-2011-200106. Epub 2011 Oct 13.; Kifer N, Sestan M, Frkovic M, et al. 2019 ACR/EULAR classification criteria and therapy in predicting organ damage accrual in patients with childhood-onset systemic lupus erythematosus: A retrospective study over the last 29 years. Lupus. 2022 Jun;31(7):828-836. doi:10.1177/09612033221094707. Epub 2022 Apr 12.; Ferreira JC, Marques HH, Ferriani MP, et al. Herpes zoster infection in childhoodonset systemic lupus erythematosus patients: a large multicenter study. Lupus. 2016 Jun; 25(7):754-9. doi:10.1177/0961203315627203. Epub 2016 Jan 27.; Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015 Oct;14(10):875-9. doi:10.1016/j.autrev.2015.05.011. Epub 2015 Jun 1.; Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109. doi:10.1186/ar2764. Epub 2009 Jul 15.; Pan L, Liu J, Liu C, et al. Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. Front Immunol. 2023 Aug 10:14: 1128754. doi:10.3389/fimmu.2023.1128754. eCollection 2023.; Danza A, Borgia I, Narvaez JI, et al. Intravenous pulses of methylprednisolone to treat flares of immune-mediated diseases: How much, how long? Lupus. 2018 Jun;27(7): 1177-1184. doi:10.1177/0961203318768888. Epub 2018 Apr 8.; Ruiz-Irastorza G., Garcia M., Espinosa G., et al. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort. Lupus Sci Med. 2016 Aug 2;3(1):e000153. doi:10.1136/lupus-2016-000153. eCollection 2016.; Tarr T, Papp G, Nagy N, et al. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus. Clin Rheumatol. 2017 Feb; 36(2):327-333. doi:10.1007/s10067-016-3492-6. Epub 2016 Nov 26.; Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011 Dec;20(14):1484-93. doi:10.1177/0961203311418269. Epub 2011 Oct 5.; Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupusBordeaux cohorts. Autoimmun Rev. 2017 Aug; 16(8):826-832. doi:10.1016/j.autrev.2017.05.017. Epub 2017 May 28.; Ruiz-Irastorza G, Ruiz-Estevez B, Lazaro E, et al. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev. 2019 Sep;18(9):102359. doi:10.1016/j.autrev.2019.102359. Epub 2019 Jul 16.; Алексеева ЕИ, Дворяковская ТМ, Никишина ИП и др. Системная красная волчанка: клинические рекомендации. Часть 2. Вопросы современной педирии. 2018; 17(2):110-25.; Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi:10.1080/14740338.2017.1269168. Epub 2016 Dec 14.; Massias JS, Smith EM, Al-Abadi E, et al. Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021 Apr;30(4):597-607. doi:10.1177/0961203320984251. Epub 2021 Jan 7.; Zahr N, Urien S, Funck-Brentano C, et al. Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus. Pharmaceuticals (Basel). 2021 Mar 17;14(3): 273. doi:10.3390/ph14030273.; Gheet FS, Dawoud HE, El-Shahaby WA, et al. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. Eur J Pediatr. 2023 Apr;182(4): 1685-1695. doi:10.1007/s00431-023-04837-0. Epub 2023 Feb 8.; Lim LSH, Pullenayegum E, Lim L, et al. From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1627-1635. doi:10.1002/acr.23199. Epub 2017 Sep 26.; Kim JW, Kim YY, Lee H, et al. Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine. J Rheumatol. 2017 Nov; 44(11):1674-1679. doi:10.3899/jrheum.170158. Epub 2017 Sep 1.; Каледа МИ, Никишина ИП. Современные международные рекомендации по диагностике и лечению системной красной волчанки с ювенильным дебютом. Научно-практическая ревматология. 2018;56(4):405-415.; Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4): 248-57. doi:10.7326/0003-4819-135-4-200108210-00009.; Cannon LA, Wenderfer SE, Lewandowski LB, et al; CARRA Lupus Nephritis Workgroup. Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America. J Rheumatol. 2022 Jun;49(6):607-614. doi:10.3899/jrheum.210428. Epub 2022 Feb 15.; Smith E, Al-Abadi E, Armon K, et al. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019 Apr;28(5):613-620. doi:10.1177/0961203319836712. Epub 2019 Mar 14.; Pennesi M, Benvenuto S. Lupus Nephritis in Children: Novel Perspectives. Medicina (Kaunas). 2023 Oct 16;59(10):1841. doi:10.3390/medicina59101841.; Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis. 2017 Sep;70(3):324-336. doi:10.1053/j.ajkd.2016.12.008. Epub 2017 Feb 21.; Mao Y, Yin L, Huang H, et al. Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res. 2019 Jan;47(1):105-113. doi:10.1177/0300060518796751. Epub 2018 Sep 12.; Chighizola CB, Ong VH, Meroni PL. The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. Clin Rev Allergy Immunol. 2017 Jun;52(3):401-423. doi:10.1007/s12016-016-8582-3.; Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):429-438. doi:10.1016/j.berh.2017.09.010. Epub 2017 Oct 11.; Wen Y, Lu P, Lu H, Hu X. Successful treatment of subdural hemorrhage and retinal hemorrhage in childhood-onset systemic lupus erythematosus associated with thrombocytopenia: Case report. Medicine (Baltimore). 2021 Jan 15;100(2):e24231. doi:10.1097/MD.0000000000024231.; Liu X, Peng Y, Cai S. The efficacy and safety of cyclosporine in children with systemic lupus erythematosus: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2023 Feb 22;102(8):e32314. doi:10.1097/MD.0000000000032314.; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40.; Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005 Oct;52(10):3168-74. doi:10.1002/art.21351.; Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and Efficacy of Rituximab in Childhood-onset Systemic Lupus Erythematosus and Other Rheumatic Diseases. J Rheumatol. 2015 Mar;42(3):541-6. doi:10.3899/jrheum.140863. Epub 2015 Jan 15.; Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015 Jan;24(1):10-7. doi:10.1177/0961203314547793. Epub 2014 Aug 12.; Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021 Oct;30(11):1829-1836. doi:10.1177/09612033211034567. Epub 2021 Jul 27.; Алексеева ЕИ, Денисова РВ, Валиева СИ и др. Эффективность и безопасность ритуксимаба у детей с системной красной волчанкой: результаты ретроспективного исследования серии случаев. Вопросы современной педиатрии. 2016;15(5):497-504.; Каледа МИ, Никишина ИП, Николаева ЕВ и др. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214.; Cinar OK, Marlais M, Al Obaidi M, et al. Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience. Lupus. 2021 Mar;30(3):527-530. doi:10.1177/0961203320981137. Epub 2020 Dec 16.; Lei L, Muhammad S, Al-Obaidi M, et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C. Pediatr Rheumatol Online J. 2018 Sep 26; 16(1):61. doi:10.1186/s12969-018-0278-1.; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383.; Brunner HI, Abud-Mendoza C, Viola DO, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi:10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22.; Brunner HI, Abud-Mendoza C, Mori M, et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi:10.1136/rmdopen-2021-001747.; Dimelow R, Ji B, Struemper H. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. Clin Pharmacol Drug Dev. 2021 Jun;10(6):622-633. doi:10.1002/cpdd.889. Epub 2020 Nov 27.; Wang D, Shan C, Liu J, et al. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study. Front Immunol. 2022 Dec 14:13:1067721. doi:10.3389/fimmu.2022.1067721. eCollection 2022.; Wang L, Liang X, Cao Z, et al. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from multicenter study. Rheumatology (Oxford). 2024 May 2;63(5): 1437-1446. doi:10.1093/rheumatology/kead406.; Akbar L, Alsagheir R, Al-Mayouf SM. Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus. Eur J Rheumatol. 2020 Sep 8;7(4):184-189. doi:10.5152/eurjrheum.2020.20087. Online ahead of print.; Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2015 Dec; 42(12):2288-95. doi:10.3899/jrheum.150470. Epub 2015 Nov 1.; Venturelli V, Isenberg DA. Targeted Therapy for SLE-What Works, What Doesn't, What's Next. J Clin Med. 2023 Apr 29;12(9): 3198. doi:10.3390/jcm12093198.; Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006-15. doi:10.1136/annrheumdis-2013-205067. Epub 2014 Jun 20.; Zhang L, Cui JY, Zhang L. Clinical efficacy and safety of sirolimus in childhood-onset systemic lupus erythematosus in real world. Medicine (Baltimore). 2022 Nov 18; 101(46):e31551. doi:10.1097/MD.0000000000031551.; Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus. 2022 Jul;31(8):998-1006. doi:10.1177/09612033221097812. Epub 2022 May 2.; Modica RF, Thatayatikom A, Bell-Brunson DH, Elder ME. Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases. Clin Rheumatol. 2023 Jul;42(7):1965-1979. doi:10.1007/s10067-023-06559-y. Epub 2023 Mar 27.; Shaw KS, Rajeh A, Le T, et al. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 Oct 2;6(10): e2338200. doi:10.1001/jamanetworkopen.2023.38200.; Pin A, Tesser A, Pastore S, et al. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020 Oct 20;21(20):7767. doi:10.3390/ijms21207767.; Rossano M, Conti EA, Bocca P, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report. Front Immunol. 2023 Dec 6:14:1288675. doi:10.3389/fimmu.2023.1288675. eCollection 2023.; Brunner HI, Martini A, Lovell DJ, Ruperto N. Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Ann Rheum Dis. 2019 Feb;78(2):162-170. doi:10.1136/annrheumdis-2018-213198. Epub 2018 Sep 19.

Availability: https://mrj.ima-press.net/mrj/article/view/1627
https://doi.org/10.14412/1996-7012-2024-4-99-105

Relationship Between Sepsis Phenotypes and Treatment Characteristics of Patients with Viral and Bacterial Pneumonia ; Связь фенотипов сепсиса с особенностями лечения пациентов с вирусной и бактериальной пневмонией

Authors: I. A. Ruslyakova, E. Z. Shamsutdinova, L. B. Gaikovaya, И. А. Руслякова, Э. З. Шамсутдинова, Л. Б. Гайковая

Source: General Reanimatology; Том 20, № 2 (2024); 29-39 ; Общая реаниматология; Том 20, № 2 (2024); 29-39 ; 2411-7110 ; 1813-9779

Subject Terms: исход, severe community-acquired pneumonia, genetically engineered biological therapy, response, outcome, тяжелая внебольничная пневмония, генно-инженерная биологическая терапия, ответная реакция

File Description: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/2392/1812; https://www.reanimatology.com/rmt/article/view/2392/1820; https://www.reanimatology.com/rmt/article/downloadSuppFile/2392/919; Авдеев С. Н., Белобородов В. Б., Белоцерковский Б. З., Грицан А. И., Дехнич А. В., Зайцев А. А., Киров М. Ю., с соавт. Тяжелая внебольничная пневмония у взрослых. Клинические рекомендации Федерации анестезиологов и реаниматологов России. Анестезиология и реаниматология. 2022; (1): 6–35. DOI:10.17116/anaesthesiology20220116.; Cavallazzi R., Furmanek S., Arnold F. W., Beavin L. A., Wunderink R. G., Niederman M. S., Ramirez J. A. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest. 2020; 158 (3): 1008–1016. DOI:10.1016/j.chest.2020.03.051. PMID: 32298730.; Rudd K. E., Johnson S. C., Agesa K. M., Shackelford K. A., Tsoi D., Kievlan D. R., Colombara D. V., et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease study. Lancet. 2020; 395 (10219): 200–211. DOI:10.1016/S0140-6736 (19)32989-7. PMID: 31954465.; Martin-Loeches I., Torres A., Nagavci B., Aliberti S., Antonelli M., Bassetti M., Bos L. D., et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023; 49 (6): 615– 632. DOI:10.1007/s00134-023-07033-8. PMID: 37012484.; Wiersinga W. J., van der Poll T. Immunopathophysiology of human sepsis. EBioMedicine. 2022; 86: 104363. DOI:10.1016/j.ebiom.2022.104363. PMID: 36470832.; Vincent J. L., van der Poll T., Marshall J. C. The end of «One Size Fits All» sepsis therapies: toward an individualized approach. Biomedicines. 2022; 10 (9): 2260. DOI:10.3390/biomedicines10092260. PMID: 36140361.; Knox D. B., Lanspa M. J., Kuttler K. G., Brewer S. C., Brown S. M. Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome. Intensive Care Med. 2015; 41 (5): 814–822. DOI:10.1007/s00134-015-3764-7. PMID: 25851384.; Bhavani S. V., Semler M., Qian E. T., Verhoef P. A., Robichaux C., Churpek M. M., Coopersmith C. M. Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med. 2022; 48 (11): 1582–1592. DOI:10.1007/s00134-022-06890-z. PMID: 36152041.; Zhang Z., Zhang G., Goyal H., Mo L., Hong Y. Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: a latent profile analysis. Crit Care. 2018; 22 (1): 347. DOI:10.1186/s13054-018-2279-3. PMID: 30563548.; Kudo D., Goto T., Uchimido R., Hayakawa M., Yamakawa K., Abe T., Shiraishi A., et al. Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies. Crit Care. 2021; 25 (1): 114. DOI:10.1186/s13054-021-03541-5. PMID: 33741010.; Scicluna B. P., van Vught L. A., Zwinderman A. H., Wiewel M. A., Davenport E. E., Burnham K. L., Nürnberg P., et al.; MARS consortium. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017; 5 (10): 816–826. DOI:10.1016/S2213-2600 (17)30294-1. PMID: 28864056.; Komorowski M., Green A., Tatham K. C., Seymour C., Antcliffe D. Sepsis biomarkers and diagnostic tools with a focus on machine learning. EBioMedicine. 2022; 86: 104394. DOI:10.1016/j.ebiom.2022.104394. PMID: 36470834.; Barichello T., Generoso J. S., Singer M., Dal-Pizzol F. Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review. Crit Care. 2022; 26 (1): 14. DOI:10.1186/s13054021-03862-5. PMID: 34991675.; da Silva J. F., Hernandez-Romieu A. C., Browning S. D., Bruce B. B., Natarajan P., Morris S. B., Gold J. A.W., et al. COVID-19 clinical phenotypes: presentation and temporal progression of disease in a cohort of hospitalized adults in Georgia, United States. Open Forum Infect Dis. 2020; 8 (1): ofaa596. DOI:10.1093/ofid/ofaa596. PMID: 33537363.; Cidade J. P., de Souza Dantas V. C., de Figueiredo Thompson A., de Miranda R. C.C.C., Mamfrim R., Caroli H., et al. Identification of distinct clinical phenotypes of critically ill COVID19 patients: results from a cohort observational study. J Clin Med. 2023; 12 (8): 3035. DOI:10.3390/jcm12083035. PMID: 37109370.; Ranard B. L., Megjhani M., Terilli K., Doyle K., Claassen J., Pinsky M. R., Clermont G., et al. Identification of endotypes of hospitalized COVID-19 patients. Front Med (Lausanne). 2021; 8: 770343. DOI:10.3389/fmed.2021.770343. PMID: 34859018.; Komorowski M. Clinical management of sepsis can be improved by artificial intelligence: yes. Intensive Care Med. 2020; 46 (2): 375–377. DOI:10.1007/s00134-019-05898-2. PMID: 31834423.; Davenport E. E., Burnham K. L., Radhakrishnan J., Humburg P., Hutton P., Mills T. C., Rautanen A., et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016; 4 (4): 259–271. DOI:10.1016/S2213-2600(16)00046-1. PMID: 26917434.; Sweeney T. E., Azad T. D., Donato M., Haynes W. A., Perumal T. M., Henao R., Bermejo-Martin J. F., et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018; 46 (6): 915–925. DOI:10.1097/CCM.0000000000003084. PMID: 29537985.; Burnham K. L., Davenport E. E., Radhakrishnan J., Humburg P., Gordon A. C., Hutton P., Svoren-Jabalera E., et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med. 2017; 196 (3): 328–339. DOI:10.1164/rccm.201608-1685OC. PMID: 28036233.; Antcliffe D. B., Burnham K. L., Al-Beidh F., Santhakumaran S., Brett S. J., Hinds C. J., Ashby D., et al. Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2019; 199 (8): 980–986. DOI:10.1164/rccm.201807-1419OC. PMID: 30365341.; Wu X., Li R., He Z., Yu T., Cheng C. A value-based deep reinforcement learning model with human expertise in optimal treatment of sepsis. NPJ Digit Med. 2023; 6 (1): 15. DOI:10.1038/s41746-023-00755-5. PMID: 36732666.; DeMerle K.M., Angus D. C., Baillie J. K., Brant E., Calfee C. S., Carcillo J., Chang C. H., et al. Sepsis subclasses: a framework for development and interpretation. Crit Care Med. 2021; 49 (5): 748–759. DOI:10.1097/CCM.0000000000004842. PMID: 33591001.; Seymour C. W., Kennedy J. N., Wang S., Chang C. H., Elliott C. F., Xu Z., Berry S., et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019; 321 (20): 2003–2017. DOI:10.1001/jama.2019.5791. PMID: 31104070.; Kalimouttou A., Lerner I., Cheurfa C., Jannot A. S., Pirracchio R. Machine-learning-derived sepsis bundle of care. Intensive Care Med. 2023; 49 (1): 26–36. DOI:10.1007/s00134-022-06928-2. PMID: 36446854.; Bruse N., Kooistra E. J., Jansen A., van Amstel R. B.E., de Keizer N. F., Kennedy J. N., Seymour C., et al. Clinical sepsis phenotypes in critically ill COVID-19 patients. Crit Care. 2022; 26 (1): 244. DOI:10.1186/s13054-022-04118-6. PMID: 35945618.; Reddy K., Sinha P., O’Kane C.M., Gordon A. C., Calfee C. S., McAuley D.F. Subphenotypes in critical care: translation into clinical practice. Lancet Respir Med. 2020; 8 (6): 631– 643. DOI:10.1016/S2213-2600(20)30124-7. PMID: 32526190.; Grasselli G., Calfee C. S., Camporota L., Poole D., Amato M. B.P., Antonelli M., Arabi Y. M., et al; European Society of Intensive Care Medicine Taskforce on ARDS. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023; 49 (7): 727–759. DOI:10.1007/s00134-023-07050-7. PMID: 37326646.; Профилактика, диагностика и лечение новой коронавирусной 2. инфекции (COVID-19). Временные методические рекомендации МЗ РФ. Версия 17 от 14.12.2022. Дата доступа: 05.09.2023. https: //static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf; Заболотских И. Б., Киров М. Ю., Лебединский К. М., Проценко Д. Н., Авдеев С. Н., Андреенко А. А., Арсентьев Л. В., с соавт. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Вестник интенсивной терапии имени А.И. Салтанова. 2022; (1): 5–140. DOI:10.21320/1818-474X-2022-1-5-140; Mandell L. A., Wunderink R. G., Anzueto A., Bartlett J. G., Campbell G. D., Dean N. C., Dowell S. F., et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2 (Suppl 2): S27–72. DOI:10.1086/511159. PMID: 17278083.; Zimmerman J. E., Kramer A. A., McNair D.S., Malila F. M. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit Care Med. 2006; 34 (5): 1297–310. DOI:10.1097/01.CCM.0000215112.84523.F0. PMID: 16540951.; Ata Ur-Rehman H. M., Ishtiaq W., Yousaf M., Bano S., Mujahid A. M., Akhtar A. Modified Nutrition Risk in Critically Ill (mNUTRIC) score to assess nutritional risk in mechanically ventilated patients: a prospective observational study from the Pakistani population. Cureus. 2018; 10 (12): e3786. DOI:10.7759/cureus.3786. PMID: 30854273.; «National Early Warning Score (NEWS) 2» https: //www.rcplondon.ac.uk/projects/outputs/national-early-warningscore-news-2.; Miyashita N., Matsushima T., Oka M., Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006; 45 (7): 419–428. DOI:10.2169/internalmedicine.45.1691. PMID: 16679695.; Charles P. G., Wolfe R., Whitby M., Fine M. J., Fuller A. J., Stirling R., Wright A. A., et al.; Australian CommunityAcquired Pneumonia Study Collaboration; Grayson M. L. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008; 47 (3): 375–384. DOI:10.1086/589754. PMID: 18558884.; Le Gall J., Lemeshow S., Saulnier F. A New Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270 (24): 2957–2963. DOI:10.1001/jama.1993.03510240069035. PMID: 8254858.; https://www.reanimatology.com/rmt/article/view/2392

Availability: https://www.reanimatology.com/rmt/article/view/2392
https://doi.org/10.15360/1813-9779-2024-2-29-40

Achievement of Control of Severe Bronchial Asthma When Using Dupilumab ; Достижение контроля тяжелой бронхиальной астмы при использовании препарата дупилумаб

Authors: O. V. Kazmerchuk, E. A. Sobko, I. V. Demko, О. В. Казмерчук, Е. А. Собко, И. В. Демко

Contributors: The authors declare no funding for this study, Авторы заявляют об отсутствии финансирования при проведении исследования

Source: The Russian Archives of Internal Medicine; Том 14, № 6 (2024); 457-466 ; Архивъ внутренней медицины; Том 14, № 6 (2024); 457-466 ; 2411-6564 ; 2226-6704

Subject Terms: генно-инженерная биологическая терапия, dupilumab, achieving control, genetically engineered biological therapy, дупилумаб, достижение контроля

File Description: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/1881/1371; https://www.medarhive.ru/jour/article/view/1881/1378; Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017; 5(9): 691–706. DOI:10.1016/S2213-2600(17)30293-X.; Деев И.А., Кобякова О.С., Стародубов В.И. Общая заболеваемость детского населения России (0-14 лет) в 2023 г. ФГБУ «ЦНИИОИЗ» Минздрава России. 2024; 154-156. DOI:10.21045/978-5-94116-160-7-2024.; Чучалин А.Г. Достижения в лечении астмы в России в первой декаде нового тысячелетия. Consilium Medicum (Экстравыпуск). 2010; 11—12.; Uphoff E, Cabieses B, Pinart M, et al. A systematic review of socioeconomic position in relation to asthma and allergic diseases. Eur RespirJ. 2015. 46(2). 364–374. DOI:10.1183/09031936.00114514.; Masefield S, Edwards J, Hansen K, et al. The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP). Eur Respir J. 2017; 49(5): 1602295. DOI:10.1183/13993003.02295-2016.; Bahadori K, Doyle-Waters MM, Marra C et al. Economic burden of asthma : a systematic review. BMC Pulm Med. 2009. 19(9). 24. DOI:10.1186/1471-2466-9-24.; Mathers CD. History of global burden of disease assessment at the World Health Organization. Arch Public Health. 2020. 24. 77-78. DOI:10.1186/s13690-020-00458-3.; Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019. 46:101. DOI:10.1016/j.smim.2019.101301.; Global Initiative for Asthma, GINA. 2023; 200-220. [Electronic resource]. URL: https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS (date of the application: 10. 08. 2024); McDowell P.J., Heaney L.G. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020; 75(2):302-310. DOI:10.1111/all.13966.; Rabe KF, Nair P, Brusselle G, Maspero JF et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018. 378:2475–85. DOI:10.1056/NEJMoa1804093.; Wechsler ME, Ford LB, Maspero JF et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022. 10:11–25. DOI:10.1016/S2213-2600(21)00322-2.; Пирогов АБ, Приходько АГ, Перельман ЮМ. Участие макрофагов и эпителия в реакции бронхов на гиперосмолярный стимул при бронхиальной астме. Сибирское медицинское обозрение. 2024. 64-71. DOI:10.20333/25000136-2024-1-64-71.; Chung K.F. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med. 2016. 192-204. DOI:10.1111/joim.12382.; Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015. 135(2). 299-310. DOI:10.1016/j.jaci.2014.12.1871.; Андрианова Г.Н., Каримова А.А. Фармакоэкономика : уч. пособие. ФГБОУ ВО УГМУ Минздрава России. Екатеринбург: Изд-во УГМУ. 2017. 196. ISBN 978-5-89895-828-2; Ягудина, Р. И. Методологические основы анализа «затраты - эффективность». Фармакоэкономика: теория и практика. 2014. Т. 2, № 2. С. 23-27.; Клинические рекомендации по бронхиальной астме Минздрава РФ. 2024; 60-80. [Электронный ресурс]. URL: http://disuria.ru/_ld/10/1037_kr21J45J46MZ.pdf?ysclid=l7un7hzve9180338084.(дата обращения: 01. 08. 2024).; Graham B.L., Steenbruggen I., Miller M.R. et al. Standardization of spirometry 2019. Update an official American Thoracic Society and European Respiratory Society technical statement. Am. J. Respir. Crit. Care Med. 2019. 70–88. DOI:10.1164/rccm.201908-1590ST.; Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020; 50(7): 789–98. DOI:10.1111/cea.13614.; Pelaia C, Lombardo N, Busceti MT, et al. Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy. 2021; 24(14): 1165–72. DOI:10.2147/JAA.S328988.; Крысанов И.С., Крысанова В.С., Ермакова В.Ю. Клинико-экономический анализ применения препарата дупилумаб при тяжёлой бронхиальной астме. Качественная клиническая практика. 2020; 5: 15-26. DOI:10.37489/2588-0519-2020-5-15-26.; https://www.medarhive.ru/jour/article/view/1881

Availability: https://www.medarhive.ru/jour/article/view/1881
https://doi.org/10.20514/2226-6704-2024-14-6-457-466

СҮЛЕЛІ ҚАБЫНБАЛЫ ІШЕК АУРУЫ ЖАРАЛЫ КОЛИТТІҢ ДИАГНОСТИКАЛЫҚ КРИТЕРИЛЕРІ ЖӘНЕ ЕМІНІҢ МҮМКІНДІКТЕРІ. ӘДЕБИЕТТІК ШОЛУ: DIAGNOSTIC CRITERIA AND TREATMENT OPTIONS FOR ULCERATIVE COLITIS. LITERATURE REVIEW

Source: Наука и здравоохранение. :66-80

Subject Terms: Ішектің сүлелі қабынбалы ауруы, воспалительная болезнь кишечника, Жаралы колит, гендік инженерлік биологиялық ем, кальпротектин, язвенный колит, тітіркенген ішек, раздраженный кишечник, calprotectin, irritable bowel, генно-инженерная биологическая терапия, Крон ауруы, inflammatory bowel disease, болезнь Крона, genetically engineered biological therapy, ulcerative colitis

Resource consumption and patient employability during systemic therapy and biological therapy

Authors: L. S. Kruglova, A. A. Hotko

Source: Качественная клиническая практика, Vol 0, Iss 1, Pp 46-55 (2021)

Subject Terms: число госпитализаций, количество обращений за амбулаторной помощью, псориаз, количество листов временной нетрудоспособности, дней временной нетрудоспособности, 3. Good health, генно-инженерная биологическая терапия, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, псориатический артрит, длительность госпитализаций, Medical technology, R855-855.5

Access URL: https://www.clinvest.ru/jour/article/download/562/574
https://doaj.org/article/9fa04cbb6b0142e0878259f5feb9a98f
https://www.clinvest.ru/jour/article/download/562/574
https://cyberleninka.ru/article/n/resursopotreblenie-i-trudosposobnost-patsientov-na-fone-primeneniya-sistemnoy-terapii-i-genno-inzhenernoy-biologicheskoy-terapii/pdf
https://www.clinvest.ru/jour/article/view/562/574
https://cyberleninka.ru/article/n/resursopotreblenie-i-trudosposobnost-patsientov-na-fone-primeneniya-sistemnoy-terapii-i-genno-inzhenernoy-biologicheskoy-terapii

Применение абатацепта у пациентов с ювенильным идиопатическим артритом – обзор клинических исследований

Subject Terms: генно-инженерная биологическая терапия, абатацепт, juvenile idiopathic arthritis, T cells, Т-лимфоциты, genetically engineered biological therapy, clinical trial, клиническое исследование, ювенильный идиопатический артрит, abatacept

Rheumatoid arthritis and COVID-19: Three years later ; Ревматоидный артрит и COVID-19: три года спустя

Authors: B. S. Belov, E. S. Aronova, G. I. Gridneva, E. I. Nasonov, Б. С. Белов, Е. С. Аронова, Г. И. Гриднева, Е. Л. Насонов

Contributors: Исследование выполнено в рамках темы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», № государственного задания 1021051503137-7

Source: Rheumatology Science and Practice; Vol 61, No 4 (2023); 450-457 ; Научно-практическая ревматология; Vol 61, No 4 (2023); 450-457 ; 1995-4492 ; 1995-4484

Subject Terms: базисные противовоспалительные препараты, infection, post-COVID syndrome, rheumatoid arthritis, immunoinflammatory rheumatic diseases, bDMARDs, DMARDs, инфекция, постковидный синдром, ревматоидный артрит, иммуновоспалительные ревматические заболевания, генно-инженерная биологическая терапия

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3399/2304; WHO coronavirus (COVID-19) dashboard. URL: https://covid19.who.int (Accessed: 31th May 2023).; Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-132. [Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):123-132 (In Russ.)]. doi:10.14412/1995-4484-2020-123-132; Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, Лила АМ, Ананьева ЛП, Лисицина ТА, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-367. [Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: At the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(4):353-367 (In Russ.)]. doi:10.47360/1995-4484-2020-353-367; Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al.; NYU WARCOV Investigators. COVID-19 in patients with inflammatory arthritis: A prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol. 2020;72(12):1981-1989. doi:10.1002/art.41456; Conway R, Nikiphorou E, Demetriou CA, Low C, Leamy K, Ryan JG, et al.; COVID-19 Global Rheumatology Alliance. Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: Data from the COVID-19 global rheumatology alliance registry. Rheumatol Adv Pract. 2021;5(2):rkab031. doi:10.1093/rap/rkab031; D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi:10.1002/art.41619; Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi:10.1136/annrheumdis-2020-217871; Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi:10.1136/annrheumdis-2020-219498; Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi:10.1136/annrheumdis-2021-220418; England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in rheumatoid arthritis: A national veterans affairs matched cohort study in at-risk individuals. Arthritis Rheumatol. 2021;73(12):2179-2188. doi:10.1002/art.41800; Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: First results of Reuma-CoV Brasil registry. RMD Open. 2021;7(1):e001461. doi:10.1136/rmdopen-2020-001461; Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology (Oxford). 2021;60(SI):SI59-SI67. doi:10.1093/rheumatology/keaa897; FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE Consortium and Contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2021;80(4):527-538. doi:10.1136/annrheumdis-2020-218310; Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi:10.1136/rmdopen-2020-001464; Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021;51(5):1057-1066. doi:10.1016/j.semarthrit.2021.08.010; Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al.; ARTIS Study Group. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: A nationwide Swedish cohort study. Ann Rheum Dis. 2021;80(8):1086-1093. doi:10.1136/annrheumdis-2021-219845; Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G, et al. Different COVID-19 outcomes among systemic rheumatic diseases: A nation-wide cohort study. Rheumatology (Oxford). 2023;62(3):1047-1056. doi:10.1093/rheumatology/keac422; Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, et al.; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639. doi:10.1001/jamanetworkopen.2021.29639; Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-García A, Tseng LY, et al.; COVID-19 Global Rheumatology Alliance. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766-775. doi:10.1002/art.42030; Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4; Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann Rheum Dis. 2016;75(6):965-973. doi:10.1136/annrheumdis-2016-209233; Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851-861. doi:10.1007/s00296-021-04803-9; Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Peach E, Bythell M, et al. COVID-19 infection, admission and death among people with rare autoimmune rheumatic disease in England: Results from the RECORDER project. Rheumatology (Oxford). 2022;61(8):3161-3171. doi:10.1093/rheumatology/keab794; Patel NJ, D’Silva KM, Li MD, Hsu TYT, DiIorio M, Fu X, et al. Assessing the severity of COVID-19 lung injury in rheumatic diseases versus the general population using deep learning-derived chest radiograph scores. Arthritis Care Res (Hoboken). 2023;75(3):657-666. doi:10.1002/acr.24883; Hsu TY, D’Silva KM, Patel NJ, Wang J, Mueller AA, Fu X, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: A retrospective, comparative cohort study. Lancet Rheumatol. 2021;3(9):e638-e647. doi:10.1016/S2665-9913(21)00140-5; Fernandez-Gutierrez B, Leon L, Madrid A, Rodriguez-Rodriguez L, Freites D, Font J, et al. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: Incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis. 2021;13:1759720X20962692. doi:10.1177/1759720X20962692; Насонов ЕЛ, Авдеева АС. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19). Научно-практическая ревматология. 2021;59(4):384-393. [Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus di sease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):384-393 (In Russ.)]. doi:10.47360/1995-4484-2021-384-393; Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz HM, et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 2021;7(3):e001896. doi:10.1136/rmdopen-2021-001896; D’Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021;33(3):255-261. doi:10.1097/BOR.0000000000000786; Li H, Wallace ZS, Sparks JA, Lu N, Wei J, Xie D, et al. Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: A general population study. Arthritis Care Res (Hoboken). 2023;75(5):956-966. doi:10.1002/acr.25028; Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO, Vallejo S, Neville MR, Patel NJ, et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: A retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022;4(11):e765-e774. doi:10.1016/S2665-9913(22)00227-2; Wang Y, D’Silva KM, Jorge AM, Li X, Lyv H, Wei J, et al. Increased risk of COVID-19 in patients with rheumatoid arthritis: A general population-based cohort study. Arthritis Care Res (Hoboken). 2022;74(5):741-747. doi:10.1002/acr.24831; Аронова ЕС, Белов БС, Гриднева ГИ. Постковидный синдром и ревматические заболевания: акцент на ревматоидный артрит (собственные данные). Медицинский совет. 2022;16(2):108-113. [Aronova ES, Belov BS, Gridneva GI. Post COVID syndrome and rheumatic diseases: Focus on rheumatoid arthritis (own data). Medical Council. 2022;16(2):108-113 (In Russ.)]. doi:10.21518/2079-701X-2022-16-2-108-113; Singh N, Madhira V, Hu C, Olex AL, Bergquist T, Fitzgerald KC, et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum. 2023;58:152149. doi:10.1016/j.semarthrit.2022.152149; Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28-33. doi:10.1038/s41591-020-01202-8; Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585): 1122-1127. doi:10.1126/science.abm8108; Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. [Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):5-30 (In Russ.)]. doi:10.47360/1995-4484-2021-5-30; Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi:10.1038/s41584-019-0337-0; Raghav PK, Mann Z, Ahluwalia SK, Rajalingam R. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. J Pharmacol Sci. 2023;152(1):1-21. doi:10.1016/j.jphs.2023.02.004; Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. doi:10.1134/S1019331622040062; Nasonov E, Samsonov M. The role of interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi:10.1016/j.biopha.2020.110698; WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for COVID-19 – Interim WHO Solidarity Trial results. N Engl J Med. 2021;384(6):497-511. doi:10.1056/NEJMoa2023184; Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19), версия 17 (09.12.2022). [Interim guidelines: Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19), version 17 (d.d. 12.09.2022) (In Russ.)]. URL: https://www.consultant.ru/document/cons_doc_LAW_347896/76f4d9e5aebc059b3c9a26fb6e57e2951afc8aca (Accessed: 27th May 2023).; van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi:10.1038/s41591-021-01643-9. Epub 2022 Jan 21. PMID: 35064248.; Schett G, Sticherling M, Neurath MF. COVID-19: Risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271-272. doi:10.1038/s41577-020-0312-7; Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9; Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194-202. doi:10.1038/s41590-021-01104-y; Di Iorio M, Cook CE, Vanni KMM, Patel NJ, D’Silva KM, Fu X, et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin Arthritis Rheum. 2022;55:152025. doi:10.1016/j.semarthrit.2022.152025; Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi:10.1038/s41598-021-95565-8; Calabrese LH. Long COVID in inflammatory rheumatic diseases – What’s in a name? Lancet Rheumatol. 2023;5(7):e364-e365. doi:10.1016/S2665-9913(23)00134-0; Zaccardelli A, Wallace ZS, Sparks JA. Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic. Curr Opin Rheumatol. 2023;35(3):175-184. doi:10.1097/BOR.0000000000000930; Насонов ЕЛ, Лила АМ, Белов БС, Аронова ЕС, Гриднева ГИ, Кудрявцева АВ, и др. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научно-практическая ревматология. 2021;59(6):666-675. [Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):666-675 (In Russ.)]. doi:10.47360/1995-4484-2021-666-675; Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y; Sen P, Naveen R, Nune A, Day J, Joshi M, Agarwal V, et al.; COVAD study group. Post-COVID-19 condition in patients with autoimmune rheumatic diseases: The COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Lancet Rheumatol. 2023;5(5):e247-e250. doi:10.1016/S2665-9913(23)00066-8; Widdifield J, Kwong JC, Chen S, Eder L, Benchimol EI, Kaplan GG, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: A population-based analysis. Lancet Rheumatol. 2022;4(6):e430-e440. doi:10.1016/S2665-9913(22)00096-0; Белов БС, Муравьева НВ, Куликов АН. Иммуногенность вакцин против SARS-CoV-2 у пациентов с ревматическими заболеваниями. Антибиотики и химиотерапия. 2022;67(5-6):70-80. [Belov BS, Muravyeva NV, Kulikov AN. Immunogenicity of vaccines against SARS-CoV-2 in patients with rheumatic diseases. Antibiotics and Chemotherapy. 2022;67(5-6):70-80 (In Russ.)]. doi:10.37489/0235-2990-2022-67-5-6-70-80; Skapenko A, Schulze-Koops H. COVID-19 vaccination in individuals with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2023;19(2):76-77. doi:10.1038/s41584-022-00892-3; Vanni KM, Patel NJ, DiIorio M, Kowalski E, Qian G, Cook CE, et al. Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: Two cases in patients on TNF inhibitor monotherapy. RMD Open. 2022;8(1):e002082. doi:10.1136/rmdopen-2021-002082; Patel NJ, Wang X, Fu X, Kawano Y, Cook C, Vanni KMM, et al. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Semin Arthritis Rheum. 2023;58:152108. doi:10.1016/j.semarthrit.2022.152108; Cordtz R, Kristensen S, Westermann R, Duch K, Pearce F, Lindhardsen J, et al. COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis. Rheumatology (Oxford). 2022;62(1):77-88. doi:10.1093/rheumatology/keac241; Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: A prospective, cohort study. Lancet Rheumatol. 2022;4(3):e177-e187. doi:10.1016/S2665-9913(21)00394-5; Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386-401. doi:10.1111/imm.13443; Watanabe T, Minaga K, Hara A, Yoshikawa T, Kamata K, Kudo M. Case report: New-onset rheumatoid arthritis following COVID-19 vaccination. Front Immunol. 2022;13:859926. doi:10.3389/fimmu.2022.859926; Safary A, Esalatmanesh K, Eftekharsadat AT, Jafari Nakjavani MR, Khabbazi A. Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination. Int Immunopharmacol. 2022;110:109061. doi:10.1016/j.intimp.2022.109061; Белов БС, Лила АМ, Насонов ЕЛ. Вакцинация против SARS-CoV-2 при ревматических заболеваниях: вопросы безопасности. Научно-практическая ревматология. 2022;60(1):21-31. [Belov BS, Lila AM, Nasonov EL. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(1):21-31 (In Russ.)]. doi:10.47360/1995-4484-2022-21-31; Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023;75(1):E1-E16. doi:10.1002/art.42372; Tavares ACFMG, de Melo AKG, Cruz VA, de Souza VA, de Carvalho JS, Machado KLLL, et al. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: A Brazilian Society of Rheumatology task force. Adv Rheumatol. 2022;62(1):3. doi:10.1186/s42358-022-00234-7; Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. [Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.)]. doi:10.47360/1995-4484-2021-239-254

Availability: https://rsp.mediar-press.net/rsp/article/view/3399
https://doi.org/10.47360/1995-4484-2023-450-457

Clinical case: switching from basic therapy with methotrexate to therapy with netakimab, an IL-17 inhibitor, in a patient with severe psoriasis ; Клинический случай: переход с базисной терапии метотрексатом на терапию ингибитором интерлейкина-17А нетакимабом у пациента с псориазом тяжелого течения

Authors: E. V. Svechnikova, S. E. Zhufina, M. A. Morzhanaeva, Е. В. Свечникова, С. Е. Жуфина, М. А. Моржанаева

Source: Meditsinskiy sovet = Medical Council; № 2 (2023); 69-74 ; Медицинский Совет; № 2 (2023); 69-74 ; 2658-5790 ; 2079-701X

Subject Terms: нетакимаб, basic therapy, genetically engineered biological therapy, netakimab, базисная терапия, генно-инженерная биологическая терапия

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7390/6591; Kaushik S.B., Lebwohl M.G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057.; Ito T., Takahashi H., Kawada A., Iizuka H., Nakagawa H., Japanese Society for Psoriasis Research. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol. 2018;45(3):293–301. https://doi.org/10.1111/1346-8138.14105.; Kamiya K., Kishimoto M., Sugai J., Komine M., Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019;20(18):4347. https://doi.org/10.3390/ijms20184347.; Swindell W.R., Johnston A., Xing X., Voorhees J.J., Elder J.T., Gudjonsson J.E. Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS One. 2013;8(11):e79253. https://doi.org/10.1371/journal.pone.0079253.; Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. https://doi.org/10.1056/NEJMra0804595.; Kolbinger F., Loesche C., Valentin M.A., Jiang X., Cheng Y., Jarvis P. et al. β‐Defensin 2 is a responsive biomarker of IL‐17A‐driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923–32.e8. https://doi.org/10.1016/j.jaci.2016.06.038.; Korman N.J. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. https://doi.org/10.1111/bjd.18245.; Griffiths C.E.M., Fava M., Miller A.H., Russell J., Ball S.G., Xu W. et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate‐to‐severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom. 2017;86(5):260–267. https://doi.org/10.1159/000479163.; Wu J.J., Sundaram M., Cloutier M., Gauthier-Loiselle M., Guerin A., Sigh R., Ganduli A. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor‐α inhibitors versus phototherapy: an observational cohort study. J Am Acad Dermatol. 2018;79(1):60–68. https://doi.org/10.1016/j.jaad.2018.02.050.; Wu J.J., Joshi A.A., Reddy S.P., Batech M., Egeberg A., Ahlehoff O., Mehta N.N. Anti‐inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol. 2018;32(8):1320–1326. https://doi.org/10.1111/jdv.14951.; Bellinato F., Gisondi P., Girolomoni G. Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. Biologics. 2021;(15):247–253. https://doi.org/10.2147/BTT.S290309.; Kostareva O., Svoeglazova A., Kolyadenko I., Nikulin A., Evdokimov S., Dzhus U. et al. Two Epitope Regions Revealed in the Complex of IL-17A and Anti-IL-17A V HH Domain. Int J Mol Sci. 2022;23(23):14904. https://doi.org/10.3390/ijms232314904.; Puig L., Bakulev A.L., Kokhan M.M., Samtsov A.V., Khairutdinov V.R., Morozova M.A. et al. Efficacy and Safety of Netakimab, A Novel AntiIL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind PlaceboControlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021;11(4):1319–1332. https://doi.org/10.1007/s13555-021-00554-4.

Availability: https://www.med-sovet.pro/jour/article/view/7390
https://doi.org/10.21518/ms2023-012

The selection of the initial drug in the treatment of severe psoriasis ; Выбор генно-инженерной биологической терапии в лечении тяжелых форм псориаза

Authors: O. V. Zhukova, S. I. Artemyeva, О. В. Жукова, С. И. Артемьева

Source: Meditsinskiy sovet = Medical Council; № 14 (2023); 24-34 ; Медицинский Совет; № 14 (2023); 24-34 ; 2658-5790 ; 2079-701X

Subject Terms: Дерматологический индекс качества жизни, psoriatic arthritis, guselkumab, genetically engineered biologic therapy, interleukin 23 inhibitors, DLQI, псориатический артрит, гуселькумаб, генно-инженерная биологическая терапия, ингибиторы интерлейкина 23

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7757/6886; Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010;185(10):5688–5691. https://doi.org/10.4049/jimmunol.1001538.; Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117. https://doi.org/10.3389/fphar.2020.00117.; Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the association between psoriasis and obesity: current evidence and treatment considerations. Curr Obesity Rep. 2020;9(3):165–178. https://doi.org/10.1007/s13679-020-00380-3.; Hjuler KF, Gormsen LC, Vendelbo MH, Egeberg A, Nielsen J, Iversen L. Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017;176(3): 732–740. https://doi.org/10.1111/bjd.15149.; Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt M, Khraishi M, Kielar D et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheumatic Dis. 2014;73(1):48–55. https://doi.org/10.1136/annrheumdis-2013-203696.; Syversen SW, Jorgensen KK, Goll GL, Brun MK, Sandanger Q, Bjorlykke KH et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375–2384. https://doi.org/10.1001/jama.2021.21316.; McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022;8(1):е002074. https://doi.org/10.1136/rmdopen-2021-002074.; Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D´Angelo S et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheumc Dis. 2021;80(5):582–590. https://doi.org/10.1136/annrheumdis2020-218808.; Mease PJ, Landewe R, Rahman P, Tahir H, Singhal A, Boettcher E et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021;7(2):е001600. https://doi.org/10.1136/rmdopen-2021-001600.; Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM et al. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. Br J Dermatol. 2021;185(6):1124–1134. https://doi.org/10.1111/bjd.20413.; Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaci D, Birt J et al. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology. 2018;57(10):1777–1788. https://doi.org/10.1093/rheumatology/key161.; Deodhar A, Helliwell PS, Boehncke W-H, Kollmeier A, Hsia EC, Subramanian RA et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF alpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–1125. https://doi.org/10.1016/s0140-6736(20)30265-8.; Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a doubleblind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230): 1126–1136. https://doi.org/10.1016/s0140-6736(20)30263-4.; Sweet K, Song Q, Loza MJ, McInnes IB, Ma K, Leander K et al. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open. 2021;7(2):е001679. https://doi.org/10.1136/rmdopen-2021-001679.; Stefan S, Loza MJ, Song Q, Mcinnes I, Sweet K. “THU0052 ustekinumab and guselkumab treatment results in differences in serum IL17A, IL17F and CRP levels in psoriatic arthritis patients: a comparison from ustekinumab ph3 and guselkumab ph2 programs.” BMJ. 2019;78(2):293. Available at: https://ard.bmj.com/content/annrheumdis/78/Suppl_2/293.1.full.pdf.; Bonifati C, Graceffa D. How effective is ustekinumab in controlling psoriatic arthritis? Dermatol Ther. 2016;(3):155–159. https://doi.org/10.1111/dth.12322.; Snekvik I, Smith CH, Nilsen TIL, Langan SM, Modalsli EH, Romundstad PR, Saunes M. Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT Study. J Invest Dermatol. 2017;137(12):2484–2490. https://doi.org/10.1016/j.jid.2017.07.822.; Petridis A, Panagakis P, Moustou E, Vergou T, Kallidis P, Mandekou-Lefaki I et al. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece. J Eur Acad Dermatol Venereol. 2018;32(5):768–775. https://doi.org/10.1111/jdv.14802.; Araujo EP, De Souza CT, Ueno M, Cintra DE, Bertolo MB, Carvalheira JB et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology. 2007;148(12):5991–5997. https://doi.org/10.1210/en.2007-0132.; Bykerk VP, Blauvelt A, Curtis JR, Gaujoux-Viala C, Kvien TK, Winthrop K et al. Associations between safety of certolizumab pegol, disease activity, and patient characteristics, including corticosteroid use and body mass index. ACR Open Rheumatol. 2021;3(8):501–511. https://doi.org/10.1002/acr2.11259.; Mahe E, Reguiai Z, Barthelemy H, Quiles-Tsimaratos, Chaby C, Esteve E et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28(2):151–159. https://doi.org/10.1111/jdv.12066.; Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013;168(5):1124–1127. https://doi.org/10.1111/bjd.12235.; Dalal RS, Allegretti JR. Ustekinumab dose optimization in Crohn disease: one size does not fit all. Inflamm Bowel Dis. 2021;27(6):e70. https://doi.org/10.1093/ibd/izab019.; Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–421. https://doi.org/10.1111/bjd.12110.; Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020;34(3):533–541. https://doi.org/10.1111/jdv.16004.; Papp K, Crowley J, Rubel D, Landells I, Song M, Wasfi Y et al. Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumabl: results from the VOYAGE 1 and 2 Trials. Acta Dermato Venereol. 2018;79(3):20. https://doi.org/10.1016/j.jaad.2018.05.378.; Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan CG et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170. https://doi.org/10.3390/jcm9072170.; Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol. 2014;12(9):1494-502.e1. https://doi.org/10.1016/j.cgh.2013.12.035.; Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. https://doi.org/10.1056/NEJMoa1602773.; Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179–2191. https://doi.org/10.1016/j.cgh.2020.01.008.; Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. https://doi.org/10.1136/gutjnl-2011-301668.; van de Kerkhof PCM, Griffiths CEM, Reich K, Leonardi CL, Blauvelt A, Tsai T-F et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98. https://doi.org/10.1016/j.jaad.2016.03.024.; Gordon KB, Colombel J-F, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis reply. N Engl J Med. 2016;375(21):2102. https://doi.org/10.1056/NEJMc1610828.; Sandborn WJ, D’Haens GR, Reinisch W, Panes J, Chan D, Gonzalez S et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650–1664. https://doi.org/10.1053/j.gastro.2022.01.047.; Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J Dermatol Treat. 2021;32(2):261–263. https://doi.org/10.1080/09546634.2019.1654067.; Grossberg LB. A case report of successful treatment of Crohn’s disease and psoriasis with guselkumab. Inflamm Bowel Dis. 2019;25(7):E84-E. https://doi.org/10.1093/ibd/izz033.; Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. https://doi.org/10.1016/j.jaad.2016.07.042.; Poizeau F, Nowak E, Kerbrat S, Le Nautout B, Droitcourt C, Drici M-D et al. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab. JAMA Dermatol. 2020;156(11):1208–1215. https://doi.org/10.1001/jamadermatol.2020.2977.; Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H et al. Longterm efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–1545. https://doi.org/10.1111/jdv.12046.; Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):58–66. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=39.%09Papp+K,+Gottlieb+AB,+Naldi+L+et+al.+Safety+surveillance+for+ustekinumab+and+other+psoriasis+treatments+from+the+Psoriasis+Longitudinal+Assessment+and+Registry+%28PSOLAR%29.+J+Drugs+Dermatology.+2015%3B14%3A5.; Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2): 345–352. https://doi.org/10.1016/j.jaad.2018.02.040.; de Brito M, Yiu ZZN. Cardiovascular Safety of biologics targeting interleukin (IL)-12 and/or IL-23: what does the evidence say? Am J Clin Dermatol. 2021;22(5):587–601. https://doi.org/10.1007/s40257-021-00612-9.; Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–1684. https://doi.org/10.1111/jdv.15653.; Blauvelt A, Tsai T-F, Langley RG, Miller M, Shen Y-K, You Y et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827–834. https://doi.org/10.1016/j.jaad.2021.11.004.; Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137(6):778–783. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=44.%09Margolis+D,+Bilker+W,+Hennessy+S,+Vittorio+C,+Santanna+J,+Strom+BL.+The+risk+of+malignancy+associated+with+psoriasis.+Arch+Dermatol.+2001%3B137%3A778%E2%80%93783.; Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119–130. https://doi.org/10.1002/pds.2046.; Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. AntiTNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies–systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285. https://doi.org/10.1001/jama.295.19.2275.; Gottlieb A, Lebwohl M, Liu C. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. Am J Clin Dermatol. 2020;21(3):421–430. https://doi.org/10.1007/s40257-020-00512-4.; Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–440. https://doi.org/10.1016/j.jaad.2016.09.026.; Papp KA, Griffiths CEM, Gordon K, Lebwohl M, Szapary Po, Wasfi Y et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. B J Dermatol. 2013;168(4):844–854. https://doi.org/10.1111/bjd.12214.; Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–751. https://doi.org/10.1016/j.jaad.2011.06.041.; Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70–80. https://doi.org/10.1016/j.jaad.2017.08.051.; Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu M-C et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457–465. https://doi.org/10.1016/j.jaad.2009.09.014.; Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom. 2017;86(5):260–267. https://doi.org/10.1159/000479163.; Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T et al. No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):E105-107. https://doi.org/10.1111/bjd.16051.; Komori T, Otsuka A, Honda Y, Kanameishi S, Honda T, Kabashima K. Exacerbation of depression in a psoriatic arthritis patient possibly induced by secukinumab. Eur J Dermatol. 2016;26(5):506–507. https://doi.org/10.1684/ejd.2016.2832.; Reich K, Gordon B, Strober BE, Armstrong AW, Miller M, Shen YK. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. British Journal of Dermatol. 2021;185(6):1146–1159. https://doi.org/10.1111/bjd.20568.

Availability: https://www.med-sovet.pro/jour/article/view/7757
https://doi.org/10.21518/ms2023-280

Case of successful use of sarilumab in secondary renal amyloidosis in a patient with rheumatoid arthritis ; Случай успешного применения сарилумаба при вторичном амилоидозе почек у пациентки с ревматоидным артритом

Authors: L. A. Smirnova, O. V. Simonova, E. N. Sukhikh, A. O. Shilyaeva, Л. А. Смирнова, О. В. Симонова, Е. Н. Сухих, А. О. Шиляева

Source: Rheumatology Science and Practice; Vol 60, No 5 (2022); 599-602 ; Научно-практическая ревматология; Vol 60, No 5 (2022); 599-602 ; 1995-4492 ; 1995-4484

Subject Terms: генно-инженерная биологическая терапия, secondary renal amyloidosis, nephrotic syndrome, chronic kidney disease, interleukin 6, genetic engineering biological therapy, вторичный амилоидоз почек, нефротический синдром, хроническая болезнь почек, ингибитор интерлейкина 6

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3229/2233; Hickson LJ, Crowson CS, Gabriel SE, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63(2):206-213. doi:10.1053/j.ajkd.2013.08.010; Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415-421. doi:10.1136/ annrheumdis-2013-204021; Оранский СП. Хроническая болезнь почек при ревматоидно артрите: ассоциация с сердечно-сосудистым риском. Фундаментальные исследования. 2013;12(2):285-288; Чеботарева НВ, Гуляев СВ, Андросова ТВ, Милованова ЛЮ. Хроническая болезнь почек у больных ревматоидным артритом: частота, факторы риска, варианты поражения почек. Терапевтический архив. 2019;91(5):129-133.; Makino H, Yoshinaga Y, Yamasaki Y, Morita Y, Hashimoto H, Yamamura M. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod Rheumatol. 2002;12(2):148-154. doi:10.3109/s101650200025; Ребров АП, Тяпкина МА, Волошина ЕВ. Субклиническое поражение почек у пациентов с ревматоидным артритом. Лечащий врач. 2012;4:40-42.; Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: Chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-213. doi:10.1080/13506129.2016.1257986; Li ZI, Chung AC, Zhou L, Huang XR, Liu F, Fu P, et al. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Lab Invest. 2011;91(6):837-851. doi:10.1038/labinvest.2011.42; Kim HW, Lee CK, Cha HS, Choe JY, Park EJ, Kim J. Effect of antitumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol Int. 2015;35(4):727-734. doi:10.1007/s00296-014-3146-4; Sumida K, Molnar MZ, Potukuchi PK, Hassan F, Thomas F, Yamagata K, et al. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018;93(5):1207-1216. doi:10.1016/j.kint.2017.11.025; Nakamura T, Kumon Y, Hirata S, Takaoka H. Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(4):501-508.; Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2010;29(12):1395-1401. doi:10.1007/s10067-010-1469-4; Okuda Y. AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019;29(2):268-274. doi:10.1080/14397595.2 018.1515145; Sato H, Sakai T, Sugaya T, Otaki Y, Aoki K, Ishii K, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009;28(9):1113-1136. doi:10.1007/s10067-009-1185-0; Симонова ОВ, Сухих ЕН, Смирнова ЛА, Тимин МВ. Клинический случай успешной трансплантации почки у пациента с вторичным амилоидозом на фоне анкилозирующего спондилоартрита. Лечащий врач. 2020;1:36-38.; Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997. doi:10.1016/S0140-6736(08)60453-5; Насонов ЕЛ. Применение тоцилизумаба при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2011;(6):46-56.

Availability: https://rsp.mediar-press.net/rsp/article/view/3229
https://doi.org/10.47360/1995-4484-2022-599-602

New options for severe asthma ; Новые возможности терапии тяжелой бронхиальной астмы

Authors: A. Yu. Kraposhina, E. A. Sobko, I. V. Demko, A. B. Katser, O. V. Kazmerchuk, Yu. I. Abramov, S. V. Chubarova, А. Ю. Крапошина, Е. А. Собко, И. В. Демко, А. Б. Кацер, О. В. Казмерчук, Ю. И. Абрамов, С. В. Чубарова

Source: Meditsinskiy sovet = Medical Council; № 18 (2022); 20-28 ; Медицинский Совет; № 18 (2022); 20-28 ; 2658-5790 ; 2079-701X

Subject Terms: эозинофильное воспаление, asthma pathogenesis, targeted therapy, genetically engineered biological therapy, T2 endotype markers, eosinophilic inflammation, патогенез астмы, таргетная терапия, генно-инженерная биологическая терапия, маркеры Т2-эндотипа

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7116/6388; Corren J. Asthma phenotypes and endotypes: an evolving paradigm for classification. Discov Med. 2013;15(83):243–249. Available at: https://www.discoverymedicine.com/Jonathan-Corren/2013/04/26/asthmaphenotypes-and-endotypes-an-evolving-paradigm-for-classification/.; Thomas M., Gruffydd-Jones K., Stonham C., Ward S., Macfarlane T.V. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians ‘3 questions’. Prim Care Respir J. 2009;18(2):83–88. https://doi.org/10.3132/pcrj.2008.00045.; Геппе Н.А., Колосова Н.Г., Кондюрина Е.Г., Малахов А.Б., Мизерницкий Ю.Л., Ревякина В.А. (ред.). Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 5-е изд. М.: Оригиналмакет; 2017. 160 с. Режим доступа: http://astgmu.ru/wp-content/uploads/2018/10/Natsionalnaya-programma-BA-u-detej.-Strategiyalecheniya-i-profilaktika.pdf.; Masoli M., Fabian D., Holt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy. 2004;59(5):469–478. https://doi.org/10.1111/j.1398-9995.2004.00526.x.; Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373(9678):1905–1917. https://doi.org/10.1016/S0140-6736(09)60326-3.; Pepper A.N., Renz H., Casale T.B., Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. J Allergy Clin Immunol Pract. 2017;5(4):909–916. https://doi.org/10.1016/j.jaip.2017.04.038.; Lötvall J., Akdis C.A., Bacharier L.B., Bjermer L., Casale T.B., Custovic A. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360. https://doi.org/10.1016/j.jaci.2010.11.037.; Carr T.F., Zeki A.A., Kraft M. Eosinophilic and Noneosinophilic Asthma. Am J Respir Crit Care Med. 2018;197(1):22–37. https://doi.org/10.1164/rccm.201611-2232PP.; Leckie M.J., ten Brinke A., Khan J., Diamant Z., O’Connor B.J., Walls C.M. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. https://doi.org/10.1016/s0140-6736(00)03496-6.; Kips J.C., O’Connor B.J., Langley S.J. Woodcock A., Kerstjens H.A.M., Postma D.S. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med. 2003;167(12):1655–1659. https://doi.org/10.1164/rccm.200206-525OC.; Svenningsen S., Nair P. Asthma Endotypes and an overview of targeted therapy for asthma. Front Med (Lausanne). 2017;4:158. https://doi.org/10.3389/fmed.2017.00158.; Moore W.C., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X. et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. https://doi.org/10.1164/rccm.200906-0896OC.; Loza M.J., Djukanovic R., Chung K.F., Horowitz D., Ma K., Branigan P. et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res. 2016;17(1):165. https://doi.org/10.1186/s12931-016-0482-9.; Lefaudeux D., De Meulder B., Loza M.J., Peffer N., Rowe A., Baribaud F. et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2016;139(6):1797–1807. https://doi.org/10.1016/j.jaci.2016.08.048.; Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. https://doi.org/10.1056/NEJMoa0808991.; Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012;42(5):650–658. https://doi.org/10.1111/j.1365-2222.2011.03929.x.; Nair P. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med. 2014;371(13):1249–1251. https://doi.org/10.1056/NEJMe1408614.; Xu X., Reitsma S., Wang D.Y., Fokkens W.J. Highlights in the advances of chronic rhinosinusitis. Allergy. 2021;76(11):3349–3358. https://doi.org/10.1111/all.14892.; Asano K., Ueki S., Tamari M., Imoto Y., Fujieda S., Taniguchi M. Adult‐onset eosinophilic airway diseases. Allergy. 2020;75(12):3087–3099. https://doi.org/10.1111/all.14620.; Vinall S.L., Townsend E.R., Pettipher R. A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes. Immunology. 2007;121(4):577–584. https://doi.org/10.1111/j.1365-2567.2007.02606.x.; Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546–3556. https://doi.org/10.1172/JCI36130.; Robinson D., Humbert M., Buhl R., Cruz A.A., Inoue H., Korom S. et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161–175. https://doi.org/10.1111/cea.12880.; Cosmi L., Liotta F., Maggi L., Annunziato F. Role of type 2innate lymphoid cells in allergic diseases. Curr Allergy Asthma Rep. 2017;17(10):66. https://doi.org/10.1007/s11882-017-0735-9.; Hammad H., de Heer H.J., Soullie T., Hoogsteden H.C., Trottein F., Lambrecht B.N. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol. 2003;171(8):3936–3940. https://doi.org/10.4049/jimmunol.171.8.3936.; Faveeuw C., Gosset P., Bureau F., Angeli V., Hirai H., Maruyama T. et al. Prostaglandin D2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur J Immunol. 2003;33(4):889–898. https://doi.org/10.1002/eji.200323330.; Gosset P., Pichavant M., Faveeuw C., Bureau F., Tonnel A.B., Trottein F. Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response. Eur J Immunol. 2005;35(5):1491–1500. https://doi.org/10.1002/eji.200425319.; Tanaka K., Hirai H., Takano S., Nakamura M., Nagata K. Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res Commun. 2004;316(4):1009–1014. https://doi.org/10.1016/j.bbrc.2004.02.151.; Wills-Karp M., Finkelman F.D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal. 2008;1(51):pe55. https://doi.org/10.1126/scisignal.1.51.pe55.; Bartemes K.R., Kephart G.M., Fox S.J., Kita H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol. 2014;134(3):671–678.e4. https://doi.org/10.1016/j.jaci.2014.06.024.; Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. https://doi.org/10.1164/rccm.200701-085OC.; Hirose K., Iwata A., Tamachi T., Nakajima H. Allergic airway inflammation: key players beyond the Th2 cell pathway. Immunol Rev. 2017;278(1):145– 161. https://doi.org/10.1111/imr.12540.; Khorasanizadeh M., Eskian M., Assa’ad A.H., Camargo C.A., Jr,, Rezaei N. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma. Int Rev Immunol. 2016;35(4):294–311. https://doi.org/10.3109/08830185.2015.1128901.; Nair P., Pizzichini M.M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993. https://doi.org/10.1056/NEJMoa0805435.; Samitas K., Zervas E., Gaga M. T2-low asthma: currentapproach to diagnosis and therapy. Curr Opin Pulm Med. 2017;23(1):48–55. https://doi.org/10.1097/MCP.0000000000000342.; Licari A., Castagnoli R., Brambilla I., Marseglia A., Tosca M.A., Marseglia G.L. et al. New approaches for identifyingand testing potential new anti-asthma agents. Expert Opin Drug Discov. 2018;13(1):51–63. https://doi.org/10.1080/17460441.2018.1396315.; Saglani S., Lloyd C.M. Eosinophils in the pathogenesis of paediatric severe asthma. Curr Opin Allergy Clin Immunol. 2014;14(2):143–148. https://doi.org/10.1097/ACI.0000000000000045.; Schleich F.N., Manise M., Sele J., Henket M., Seidel L., Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11. https://doi.org/10.1186/1471-2466-13-11.; Cowan D.C., Taylor D.R., Peterson L.E., Cowan J.O., Palmay R., Williamson A. et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015;135(4):877–883.e1. https://doi.org/10.1016/j.jaci.2014.10.026.; Price D., Wilson A.M., Chisholm A., Rigazio A., Burden A., Thomas M. et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1–12. https://doi.org/10.2147/JAA.S97973.; Busse W., Spector S., Rosen K., Wang Y., Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485–486.e11. https://doi.org/10.1016/j.jaci.2013.02.032.; Wagener A.H., de Nijs S.B., Lutter R., Sousa A.R., Weersink E.J., Bel E.H. et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115– 120. https://doi.org/10.1136/thoraxjnl-2014-205634.; Ullmann N., Bossley C.J., Fleming L., Silvestri M., Bush A., Saglani S. Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma. Allergy. 2013;68(3):402–406. https://doi.org/10.1111/all.12101.; Bjerregaard A., Laing I.A., Backer V., Sverrild A., Khoo S.K., Chidlow G. et al. High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations: a prospective cohort study. Clin Exp Allergy. 2017;47(8):1007–1013. https://doi.org/10.1111/cea.12935.; Baraldi E., de Jongste J.C. European Respiratory Society/American Thoracic Society (ERS/ATS). Task Force. Measurement of exhaled nitric oxide in children, 2001. Eur Respir J. 2002;20(1):223–237. https://doi.org/10.1183/09031936.02.00293102.; Dweik R.A., Boggs P.B., Erzurum S.C., Irvin C.G., Leigh M.W., Lundberg J.O. et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. https://doi.org/10.1164/rccm.9120-11ST.; Pijnenburg M.W., De Jongste J.C. Exhaled nitric oxide in childhood asthma: a review. Clin Exp Allergy. 2008;38(2):246–259. https://doi.org/10.1111/j.1365-2222.2007.02897.x.; Giannetti M.P., Cardet J.C. Interleukin-5 antagonists usher in a new generation of asthma therapy. Curr Allergy Asthma Rep. 2016;16(11):80. https://doi.org/10.1007/s11882-016-0662-1.; Nannini L.J. Treat to target approach for asthma. J Asthma. 2020;57(6):687– 690. https://doi.org/10.1080/02770903.2019.1591443.; Normansell R., Walker S., Milan S.J., Walters E.H., Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. https://doi.org/10.1002/14651858.CD003559.pub4.; Farne H.A., Wilson A., Powell C., Bax L., Milan S.J. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;(9):CD010834. https://doi.org/10.1002/14651858.CD010834.pub3.; Zayed Y., Kheiri B., Banifadel M., Hicks M., Aburahma A., Hamid K. et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019;56(10):1110–1119. https://doi.org/10.1080/02770903.2018.1520865.; Fajt M.L., Wenzel S.E. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299–310. https://doi.org/10.1016/j.jaci.2014.12.1871.; Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. https://doi.org/10.1164/rccm.200208-789OC.; Pavord I., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. https://doi.org/10.1016/S0140-6736(12)60988-X.; Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83(6):520–528. https://doi.org/10.1159/000334701.; Tajiri T., Niimi A., Matsumoto H., Ito I., Oguma T., Otsuka K. et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014;113(4):470–475. https://doi.org/10.1016/j.anai.2014.06.004.; Tajiri T., Matsumoto H., Hiraumi H., Ikeda H., Morita K., Izuhara K. et al. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol. 2013;110(5):387–388. https://doi.org/10.1016/j.anai.2013.01.024.; Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466. https://doi.org/10.1056/NEJMoa1304048.; Wechsler M.E. Inhibiting IL-4 and IL-13 in difficult-to-control asthma. N Engl J Med. 2013;368(26):2511–2513. https://doi.org/10.1056/NEJMe1305426.; Garlisi C.G., Kung T.T., Wang P., Minnicozzi M., Umland S.P., Chapman R.W. et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol. 1999;20(2):248–255. https://doi.org/10.1165/ajrcmb.20.2.3327.; Ortega H.G., Liu M.C., Pavord I.D., Brusselle G.G., FitzGerald J.M., Chetta A. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. https://doi.org/10.1056/NEJMoa1403290.; Castro M., Mathur S., Hargreave F. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. https://doi.org/10.1164/rccm.201103-0396OC.; Castro M., Zangrilli J., Wechsler M.E., Bateman E.D., Brusselle G.G., Bardin P. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. https://doi.org/10.1016/S2213-2600(15)00042-9.; Mukherjee M., Paramo F.A., Kjarsgaard M., Salter B., Nair G., LaVigne N. et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46. https://doi.org/10.1164/rccm.201707-1323OC.; Walsh G.M. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs. 2010;11(11):1305–1312. Available at: https://pubmed.ncbi.nlm.nih.gov/21157650/.; May R.D., Monk P.D., Cohen E.S., Manuel D., Dempsey F., Davis N.H.E. et al. Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol. 2012;166(1):177–193. https://doi.org/10.1111/j.1476-5381.2011.01659.x.; Piper E., Brightling C., Niven R., Oh C., Faggioni R., Poon K. et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338. https://doi.org/10.1183/09031936.00223411.; Noonan M., Korenblat P., Mosesova S., Scheerens H. , Arron J.R., Zheng Y. et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013;132(3):567–574. https://doi.org/10.1016/j.jaci.2013.03.051.; Diamant Z., Gauvreau G.M., Cockcroft D.W., Boulet L.P., Sterk P.J., de Jongh F.H.C. et al. Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol. 2013;132(5):1045–1055.e6. https://doi.org/10.1016/j.jaci.2013.08.023.; Scheerens H., Arron J.R., Zheng Y., Erickson R.W., Choy D.F., Harris J.M. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014;44(1):38–46. https://doi.org/10.1111/cea.12220.; Jiang H., Harris M.B., Rothman P. IL-4/IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105(6 Pt 1):1063–1070. https://doi.org/10.1067/mai.2000.107604.; Liu Y., Zhang S., Li D.W., Jiang S.J. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS ONE. 2013;8(3):e59872. https://doi.org/10.1371/journal.pone.0059872.; Parker J.M., Oh C.K., LaForce C., Miller S.D., Pearlman D.S., Le C. et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011;11:14. https://doi.org/10.1186/1471-2466-11-14.; Cheng G., Arima M., Honda K., Hirata H., Eda F., Yoshida N. et al. Antiinterleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 2002;166(3):409–416. https://doi.org/10.1164/rccm.2105079.; Yang G., Li L., Volk A., Emmell E., Petley T., Giles-Komar J. et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther. 2005;313(1):8–15. https://doi.org/10.1124/jpet.104.076133.; Singh D., Kane B., Molfino N.A., Faggioni R., Roskos L., Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med. 2010;10:3. https://doi.org/10.1186/1471-2466-10-3.; Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R. et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098. https://doi.org/10.1056/NEJMoa1106469.; Laviolette M., Gossage D., Gauvreau G., Leigh R., Olivenstein R., Katial R. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096. https://doi.org/10.1016/j.jaci.2013.05.020.; Pérez de Llano L.A., Cosío B.G., Domingo C., Urrutia I., Bobolea I., Valero A. et al. Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: A multicenter, open-label pilot study. J Allergy Clin Immunol Pract. 2019;7(7):2277–2283.e2. https://doi.org/10.1016/j.jaip.2019.01.017.; Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. https://doi.org/10.1016/S0140-6736(16)31324-1.; FitzGerald J.M., Bleecker E., Nair P., Korn S., Ohta K., Lommatzsch M. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. https://doi.org/10.1016/S0140-6736(16)31322-8.; Parulekar A.D., Diamant Z., Hanania N.A. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr Opin Pulm Med. 2017;23(1):3–11. https://doi.org/10.1097/MCP.0000000000000343.; Menzies-Gow A., Ponnarambil S., Downie J., Bowen K., Hellqvist Å., Colice G. DESTINATION: a phase 3, multicentre, randomized, doubleblind, placebo-controlled, parallel-group trial to evaluate the longterm safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):279. https://doi.org/10.1186/s12931-020-01541-7.; Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013.

Availability: https://www.med-sovet.pro/jour/article/view/7116
https://doi.org/10.21518/2079-701X-2022-16-18-20-28

Клинический случай ревматоидного серонегативного полиартрита на фоне латентной туберкулезной инфекции

Authors: Фентисов, В. В.

Subject Terms: медицина, внутренние болезни, ревматоидный артрит, генно-инженерная биологическая терапия, латентная туберкулезная инфекция

Relation: http://dspace.bsu.edu.ru/handle/123456789/52749

Availability: http://dspace.bsu.edu.ru/handle/123456789/52749

Biological Therapy Survivability in Children with Psoriasis: Cohort Study ; Выживаемость биологической терапии у детей, страдающих псориазом: когортное исследование

Authors: Roman A. Ivanov, Nikolay N. Murashkin, Р. А. Иванов, Н. Н. Мурашкин

Contributors: The article has been funded by Johnson & Johnson., Статья подготовлена при финансовой поддержке компании Johnson & Johnson.

Source: Current Pediatrics; Том 20, № 5 (2021); 451-458 ; Вопросы современной педиатрии; Том 20, № 5 (2021); 451-458 ; 1682-5535 ; 1682-5527

Subject Terms: бионаивность, children, survivability, genetically engineered biological therapy, ustekinumab, adalimumab, etanercept, bionaive, дети, выживаемость, генно-инженерная биологическая терапия, устекинумаб, адалимумаб, этанерцепт

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2746/1087; Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Europ Acad Dermatol Venereol. 2016;31(2):205-212. doi:10.1111/jdv.13854; Murzina E. Pediatric Psoriasis: Clinical Features and Course. OAJBS. 2020;1(5):207-209. doi:10.38125/OAJBS.000147; Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-636. doi:10.1111/j.1365-2133.2009.09593.x; Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-1541. doi:10.1001/archderm.141.12.1537; Кубанов А.А., Богданова Е.В. Организация и результаты оказания медицинской помощи по профилю «дерматовенерология» в Российской Федерации. Итоги 2018 года // Вестник дерматологии и венерологии. — 2019. — Т. 95. — № 4. — С. 8-23. doi:10.25208/0042-4609-2019-95-4-8-23; Torrelo A. The use of biologics for childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1816-1816. doi:10.1111/jdv.15855; Cramer JA, Roy A, Burrell A, et al. Medication Compliance and Persistence: Terminology and Definitions. Value Health. 2008;11(1):44-47. doi:10.1111/j.1524-4733.2007.00213.x; Phan C, Beauchet A, Burztejn A-C, et al. Biological treatments for paediatric psoriasis: A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1984-1992. doi:10.1111/jdv.15579; Augustin M, Krger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter crosssectional study in Germany. Dermatology. 2008;216(4):366-372. doi:10.1159/000119415; Соколовский Е.В., Круглова Л.С., Понич Е.С. «Болевые» точки системной терапии биологическими препаратами при псориазе // Российский журнал кожных и венерических болезней. — 2015. — Т. 18. — № 6. — С. 32-38.; Лесная И.Н., Фриго Н.В., Каганова Н.Л. и др. Молекулярные маркеры в прогнозировании клинической эффективности инфликсимаба у больных псориазом // Вестник дерматологии и венерологии. — 2010. — Т. 86. — № 1. — C. 57-66. doi:10.25208/vdv827

Availability: https://vsp.spr-journal.ru/jour/article/view/2746
https://doi.org/10.15690/vsp.v20i5.2323

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system ; Клинико-экономический анализ применения иксекизумаба у взрослых пациентов с активным псориатическим артритом в условиях здравоохранения Российской Федерации

Authors: E. A. Pyadushkina, E. V. Derkach, M. Yu. Frolov, V. A. Rogov, A. S. Salasyuk, Е. А. Пядушкина, Е. В. Деркач, М. Ю. Фролов, В. А. Рогов, А. С. Саласюк

Contributors: Lilly Pharma sponsored the study «Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system», «Лилли фарма» спонсировала исследование «Клинико-экономический анализ применения иксекизумаба у взрослых пациентов с активным псориатическим артритом в условиях здравоохранения РФ»

Source: Modern Rheumatology Journal; Том 15, № 1 (2021); 119-127 ; Современная ревматология; Том 15, № 1 (2021); 119-127 ; 2310-158X ; 1996-7012

Subject Terms: влияние на бюджет, biologic disease-modifying antirheumatic drugs, ixekizumab, secukinumab, ustekinumab, budget impact, генно-инженерная биологическая терапия, иксекизумаб, секукинумаб, устекинумаб

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1110/1068; Коротаева ТВ, Корсакова ЮЛ, Логинова ЕЮ и др. Псориатический артрит. Клинические рекомендации по диагностике и лечению. Современная ревматология. 2018;12(2):22–35. doi:10.14412/1996-7012-2018-2-22-35; Статистический сборник «Общая заболеваемость взрослого населения России в 2017 году» https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnyematerialy/statisticheskiy-sbornik-2017-god; Статистический сборник «Заболеваемость всего населения России в 2017 году» https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnyematerialy/statisticheskiy-sbornik-2017-god; Статистический сборник «Заболеваемость взрослого населения России в 2017 году» https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnyematerialy/statisticheskiy-sbornik-2017-god; Лила АМ, Насонов ЕЛ, Коротаева ТВ. Псориатический артрит: патогенетические особенности и инновационные методы терапии. Научно-практическая ревматология. 2018;56(6):685-91.; Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/; Коротаева ТВ. Новые возможности ГИБП в терапии псориатического артрита: фокус на иксекизумаб. Opinion Leader. 2019;(9):60-6.; Распоряжение Правительства Российской Федерации от 23 ноября 2020 г. № 3073-р «Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2021 год, перечня лекарственных препаратов для медицинского применения, в том числе лекарственных препаратов для медицинского применения, назначаемых по решению врачебных комиссий медицинских организаций, перечня лекарственных препаратов, предназначенных для обеспечения лиц, больных гемофилией, муковисцидозом, гипофизарным нанизмом, болезнью Гоше, а также минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». http://static.government.ru/media/files/XSa8p7I5b5HKbAYd2xmfvVzBsosxagSe.pdf; Постановление Правительства Российской Федерации от 7 декабря 2019 г. №1610 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2020 год и на плановый период 2021 и 2022 годов». https://tyumen.ldc.ru/userfiles/public/postanovlenie-1610.pdfhttps://tyumen.ldc.ru/userfiles/public/postanovlenie-1610.pdf; Коротаева ТВ, Корсакова ЮЛ, Логинова ЕЮ и др. Оптимизация диагностики, системы мониторинга и лечения псориатического артрита в реальной практике: общие принципы организации общероссийского регистра пациентов с псориатическим артритом. Научно-практическая ревматология. 2019;55(4):407-14. doi:10.14412/1995-4484-2019-407-414; Государственный реестр лекарственных средств. Инструкция по медицинскому применению препарата Талс. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c819bbb6-be51-4ff5-9344-050d1084f6a1&t=; National Institute for Health and Care Excellence. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs. [TA537]. https://www.nice.org.uk/guidance/ta537; Протокол Совещания профильной комиссии Экспертного совета Минздрава России по специальности «Ревматология» №23 от 28 сентября 2019 г. Научно-практическая ревматология. 2019;57(5):604-7.; Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата, утвержденные приказом ФГБУ «Центр экспертизы и контроля качества медицинской помощи» Минздрава России от 29 декабря 2018 г. №242-од. https://rosmedex.ru/hta/recom/; Методические рекомендации по оценке влияния на бюджет в рамках реализации программы государственных гарантий бесплатного оказания гражданам медицинской помощи, утвержденные приказом ФГБУ «Центр экспертизы и контроля качества медицинской помощи» Минздрава России от 29 декабря 2018 г. №242-од. https://rosmedex.ru/hta/recom/; Wu D, Yue J, Tam LS. Efficacy and safety of biologics targeting interleukin-6,-12/23 and-17 pathways for peripheral psoriatic arthritis: a network meta-analysis. Rheumatology (Oxford). 2018 Mar 1;57(3):563-71. doi:10.1093/rheumatology/kex452.; Реброва ОЮ, Федяева ВК. Вопросник для оценки достоверности сетевого метаанализа (в том числе непрямых и смешанных сравнений). Медицинские технологии. Оценка и выбор. 2016;(2):48-54.; Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision-making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014 Mar;17(2):157-73. doi:10.1016/j.jval.2014.01.004.; Данные о предельных размерах оптовых надбавок и предельных размерах розничных надбавок к ценам на жизненно необходимые и важнейшие лекарственные препараты, установленные в субъектах Российской Федерации (данные на 10 февраля 2020https://fas.gov.ru/documents/686367; Оценка численности постоянного населения на 1 января 2020 года и в среднем за 2019 г. Федеральная служба государственной статистики. http://www.gks.ru/free_doc/new_site/population/demo/Popul2020.xls; Инструкция по применению лекарственного препарата для медицинского применения Козэнтикс (секукинумаб). https://grls.rosminzdrav.ru/GRLS.aspx; Инструкция по применению лекарственного препарата для медицинского применения Стелара (устекинумаб). https://grls.rosminzdrav.ru/GRLS.aspx; Walpole SC, Prieto-Merino D, Edwards P, et al. The weight of nations: an estimation of adult human biomass. BMC Public Health. 2012 Jun 18;12:439. doi:10.1186/1471-2458-12-439.; Лила АМ, Древаль РО, Шипицын ВВ. Оценка организации медицинской помощи и лекарственного обеспечения при ревматических заболеваниях и социально-экономического бремени этих болезней в Российской Федерации. Современная ревматология. 2018;12(3):112–9. doi:10.14412/1996-7012-2018-3-112-119

Availability: https://mrj.ima-press.net/mrj/article/view/1110
https://doi.org/10.14412/1996-7012-2021-1-119-127

Magnetic resonance tomography capabilities and limitations in managing the efficacy of treatment with biological disease modifying anti-rheumatic drugs in ankylosing spondylitis ; Возможности и ограничения магнитно-резонансной томографии в определении эффективности генно-инженерной биологической терапии при анкилозирующем спондилите

Authors: P. A. Shesternya, O. D. Gritsenko, P. A. Astanin, A. Yu. Stepanenko, N. V. Popov, П. А. Шестерня, О. Д. Гриценко, П. А. Астанин, А. Ю. Степаненко, Н. В. Попов

Contributors: The investigation has been conducted within scientific topic № AAA-A20-120022890005-5 «Personified Clinicoimmunological Strategy of spondyloarthritis treatment with biological disease modifying anti-rheumatic drugs», Работа выполнена в рамках Государственного задания Минзрава России «Персонифицированная клинико-иммунологическая стратегия генно-инженерной биологической терапии спондилоартрита» (№АААА-А20-120022890005-5)

Source: Modern Rheumatology Journal; Том 15, № 2 (2021); 29-34 ; Современная ревматология; Том 15, № 2 (2021); 29-34 ; 2310-158X ; 1996-7012

Subject Terms: ремиссия, axial spondyloarthritis, Magnetic resonance imaging (MRI), biological disease modifying anti-rheumatic drugs therapy (bDMARDs), sacroiliitis, remission, аксиальный спондилоартрит, магнитно-резонансная томография, генно-инженерная биологическая терапия, сакроилиит

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1119/1078; Румянцева ДГ, Эрдес ШФ. Аксиальный спондилоартрит: современный взгляд на концепцию и эволюцию болезни. Современная ревматология. 2019;13(4):4-10. doi:10/14412/1996-7012-2019-4-4-10; Bennett AN, Marzo-Ortega H, KaurPapadakis D, et al. The use of magnetic resonance imaging in axial spondyloarthritis: time to bridge the gap between radiologists and rheumatologists. J Rheumatol. 2017 Jun; 44(6):780-5. doi:10.3899/jrheum.161337. Epub 2017 Apr 1.; Baraliakos X, Richter A, Feldmann D, et al. Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population? Ann Rheum Dis. 2020 Nov 25; annrheumdis-2020-218669. doi:10.1136/annrheumdis-2020-218669. Online ahead of print.; Chan SC, Li PH, Lee KH, et al. Diagnostic utility of whole spine and thoracic spine MRI corner inflammatory lesions in axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2020 Nov 24;12: 1759720X20973922. doi:10.1177/1759720X20973922. eCollection 2020.; Bakker PAC, Ramiro S, Ez-Zaitouni Z, et al. Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis? Arthritis Rheumatol. 2019 Mar;71(3):382-91. doi:10.1002/art.40718. Epub 2019 Feb 6.; Гайдукова ИЗ, Ребров АП, Коротаева ТВ, и др. Ремиссия при аксиальных спондилоартритах – определение и инструменты оценки (рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации Ассоциация ревматологов России.). Научно-практическая ревматология. 2018;56(1):10-4.; Andreasen RA, Kristensen LE, Baraliakos X, et al. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. Arthritis Res Ther. 2020 Jul 25;22(1):177. doi:10.1186/s13075-020-02262-4.; Schwartzman M, Maksymowych WP. Is there a role for MRI to establish treatment indications and effectively monitor response in patients with axial spondyloarthritis? Rheum Dis Clin North Am. 2019 Aug;45(3): 341-58. doi:10.1016/j.rdc.2019.04.009. Epub 2019 Jun 5.; Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct; 71(10):1285-99. doi:10.1002/acr.24025. Epub 2019 Aug 21.; Machado PM, Landewe R, van der Heijde D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018 Oct; 77(10):1539-40. doi:10.1136/annrheumdis2018-213184. Epub 2018 Feb 16.; Эрдес Ш, Смирнов АВ. Технология диагностики воспалительных изменений скелета при анкилозирующем спондилите по данным магнитно-резонансной томографии. Научно-практическая ревматология. 2019;57(6):678-84.; Madari Q, Sepriano A, Ramiro S, et al. 5-year follow- up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the Desir cohort. RMD Open. 2020 Feb;6(1):e001093. doi:10.1136/rmdopen-2019-001093.; Huang Y, Chen Y, Liu T, et al. Impact of tumor necrosis factor α inhibitors on MRI inflammation in axial spondyloarthritis assessed by Spondyloarthritis Research Consortium Canada score: A metaanalysis. PLoS One. 2020 Dec 31;15(12):e0244788. doi:10.1371/journal.pone.0244788. eCollection 2020.; Эрдес Ш, Румянцева ДГ, Смирнов АВ и др. Активность заболевания и двухлетняя динамика изменений крестцово-подвздошных суставов по данным инструментальных методов исследованияу больных ранним аксиальным спондилоартритом когорты КоРСАр. Научно-практическая ревматология. 2019;57(2):186-90.; Krabbe S, Eshed I, S∅rensen IJ, et al. Novel whole-body magnetic resonance imaging response and remission criteria document diminished inflammation during golimumab treatment in axial spondyloarthritis. Rheumatology (Oxford). 2020 Nov 1;59(11): 3358-68. doi:10.1093/rheumatology/keaa153.; Smolen JS, Schö ls M, Braun J, et al. Treating axial spondyloarthritis and peripher al spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi:10.1136/annrheumdis-2017-211734; Акулова АИ, Дорогойкина КД, Гайдукова ИЗ и др. Качество жизни пациентов со спондилоартритами, получающих генно-инженерную биологическую терапию. Современная ревматология. 2019; 13(4):36-40. doi:10.14412/1996-7012-2019-4-36-40

Availability: https://mrj.ima-press.net/mrj/article/view/1119
https://doi.org/10.14412/1996-7012-2021-2-29-34